

# Cardiac-Resynchronization Therapy for Mild-to-Moderate

New England Journal of Medicine

363, 2385-2395

DOI: [10.1056/nejmoa1009540](https://doi.org/10.1056/nejmoa1009540)

Citation Report

#	ARTICLE	IF	CITATIONS
1	RFLP for a human cytochrome P-450 gene at 19q13.1 - qter (HGM8 provisional designation CYP1). Nucleic Acids Research, 1985, 13, 4610-4610.	6.5	17
2	DNA damage repair and transcription. Cellular and Molecular Life Sciences, 2004, 61, 2173-80.	2.4	23
3	Preventing Heart Failure and Improving Survival. New England Journal of Medicine, 2010, 363, 2456-2457.	13.9	6
4	Devices for heart failure. Medicine, 2010, 38, 479-483.	0.2	0
5	DETECTION OF REGIONAL LOW MYOCARDIAL PERFUSION HELPS PREDICT A RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY: FIND INDEX BY NUCLEAR IMAGING FOR DYSSYNCHRONY (FIND) STUDY. Journal of the American College of Cardiology, 2010, 55, A24.E225.	1.2	0
6	Remote monitoring via implanted devices in heart failure: rising star or lame duck?. European Journal of Heart Failure, 2011, 13, 925-926.	2.9	2
7	The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. European Journal of Heart Failure, 2011, 13, 974-983.	2.9	91
8	Chronic Heart Failure in Older Adults. Medical Clinics of North America, 2011, 95, 439-461.	1.1	15
9	Wood shop, Sun Tzu, and patient selection for cardiac resynchronization therapy. Heart Rhythm, 2011, 8, 1095-1098.	0.3	6
10	Response to cardiac resynchronization therapy: Substrate matters. Heart Rhythm, 2011, 8, 383-384.	0.3	1
11	HRS Policy Statement: Clinical Cardiac Electrophysiology Fellowship Curriculum: Update 2011. Heart Rhythm, 2011, 8, 1340-1356.	0.3	13
12	Cost-effectiveness of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2011, 3, 421-440.	0.7	0
13	Percutaneous intravascular defibrillator: Preliminary data and many questions. Heart Rhythm, 2011, 8, 293-294.	0.3	0
14	Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: A systematic review. Heart Rhythm, 2011, 8, 1083-1087.	0.3	64
15	Expanding the Use of Cardiac Resynchronization Therapy: Words of Caution. Cardiac Electrophysiology Clinics, 2011, 3, 529-537.	0.7	1
16	Almanac 2011: heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa De Cardiologia, 2011, 30, 941-948.	0.2	0
17	Terapia de resincronizaci3n en la insuficiencia card3aca. Cirugia Cardiovascular, 2011, 18, 133-143.	0.1	0
18	Prolonged QRS duration and sudden cardiac death risk stratification: Not yet ready for prime time. Heart Rhythm, 2011, 8, 1568-1569.	0.3	1

#	ARTICLE	IF	CITATIONS
19	The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. <i>Heart Rhythm</i> , 2011, 8, 679-684.	0.3	106
22	Cardiac Resynchronization Therapy in Patients With Minimal Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 58, 935-941.	1.2	74
23	Device Therapy in Heart Failure Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 889-896.	1.2	50
24	The Year in Clinical Cardiac Electrophysiology. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1645-1655.	1.2	0
25	Guiding Left Ventricular Lead Positioning and Refining Ability to Predict Response and Nonresponse to Cardiac Resynchronization Therapy Using dP/dtmax. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1137-1139.	1.2	2
26	Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: A systematic review and meta-analysis. <i>Heart Rhythm</i> , 2011, 8, 1088-1094.	0.3	216
27	Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. <i>American Heart Journal</i> , 2011, 161, 1024-1030.e3.	1.2	196
28	New and Emerging Drugs and Device Therapies for Chronic Heart Failure in Patients With Systolic Ventricular Dysfunction. <i>Canadian Journal of Cardiology</i> , 2011, 27, 296-301.	0.8	15
29	The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. <i>Canadian Journal of Cardiology</i> , 2011, 27, 319-338.	0.8	139
30	Association of Rate-Controlled Persistent Atrial Fibrillation With Clinical Outcome and Ventricular Remodelling in Recipients of Cardiac Resynchronization Therapy. <i>Canadian Journal of Cardiology</i> , 2011, 27, 787-793.	0.8	18
31	Mortality Reduction of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Heart Failure: An Updated Meta-Analysis. Does Recent Evidence Change the Standard of Care?. <i>Journal of Cardiac Failure</i> , 2011, 17, 860-866.	0.7	19
32	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago, Estados Unidos, 13-17 de noviembre de 2010). <i>Revista Espanola De Cardiologia</i> , 2011, 64, 59.e1-59.e8.	0.6	15
33	Advances in cardiology: clinical trial update. <i>Future Cardiology</i> , 2011, 7, 299-310.	0.5	4
34	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Chicago, United States, November 13-17, 2010). <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq1.4 0.784814 rgBT	0.4	14
35	Almanac 2011: heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2011, 30, 941-948.	0.2	0
36	Implantable cardioverter defibrillators and cardiac resynchronisation therapy. <i>Lancet</i> , The, 2011, 378, 722-730.	6.3	45
37	2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. <i>Medical Journal of Australia</i> , 2011, 194, 405-409.	0.8	128
38	Rhetorical Techniques Used in the Reporting of Cardiac Resynchronization Trials. <i>Archives of Internal Medicine</i> , 2011, 171, 1500.	4.3	5

#	ARTICLE	IF	CITATIONS
39	Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients. , O, , .		0
40	Role of atrioventricular nodal ablation and pacemaker therapy in elderly patients with recurrent atrial fibrillation. <i>Interventional Cardiology</i> , 2011, 3, 713-720.	0.0	1
41	Meta-analysis: Cardiac Resynchronization Therapy for Patients With Less Symptomatic Heart Failure. <i>Annals of Internal Medicine</i> , 2011, 154, 401.	2.0	113
42	Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline. <i>Annals of Internal Medicine</i> , 2011, 155, 252.	2.0	49
43	Translating the Benefits of Cardiac Resynchronization Therapy Widely and Wisely: Challenges Remain. <i>Annals of Internal Medicine</i> , 2011, 154, 436.	2.0	3
45	The CRT Monopoly Game. <i>Circulation Journal</i> , 2011, 75, 1053-1054.	0.7	0
46	Cardiac Resynchronization Therapy - Refocus on the Electrical Substrate -. <i>Circulation Journal</i> , 2011, 75, 1297-1304.	0.7	25
47	Non-Responders to Cardiac Resynchronization Therapy - The Magnitude of the Problem and the Issues -. <i>Circulation Journal</i> , 2011, 75, 521-527.	0.7	209
48	Acute heart failure syndromes: assessment and reconstructing the heart. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 258-263.	0.6	5
49	Safety and Effectiveness of Primary Prevention Cardioverter defibrillators in Octogenarians. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 900-906.	0.5	18
50	CRT Outcomes: Luck versus Skill. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 783-784.	0.5	0
51	Developments in Heart Failure 2010. <i>Congestive Heart Failure</i> , 2011, 17, 92-100.	2.0	3
52	Device Therapy in Advanced Heart Failure: What to Put In and What to Turn Off. <i>Congestive Heart Failure</i> , 2011, 17, 220-226.	2.0	4
54	Evolutionary innovations in cardiac pacing. <i>Journal of Electrocardiology</i> , 2011, 44, 611-615.	0.4	23
55	Establishing Prognosis in Heart Failure: A Multimarker Approach. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 86-96.	1.6	45
56	Comparison of Long-Term Survival of Men Versus Women With Heart Failure Treated With Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2011, 108, 63-68.	0.7	39
57	Best Clinical Trials Reported in 2010. <i>American Journal of Cardiology</i> , 2011, 108, 162-168.	0.7	0
58	Effect of Cardiac Resynchronization Therapy-Defibrillator Implantation on Health Status in Patients With Mild Versus Moderate Symptoms of Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 1155-1159.	0.7	5

#	ARTICLE	IF	CITATIONS
59	Predictors of Response to Cardiac Resynchronization Therapy in Patients With a Non-Left Bundle Branch Block Morphology. <i>American Journal of Cardiology</i> , 2011, 108, 1576-1580.	0.7	45
60	Specialized heart failure nurses in a high-tech world. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2011, 40, 276-277.	0.8	0
61	Cardiac resynchronisation improves survival in mild heart failure!. <i>Netherlands Heart Journal</i> , 2011, 19, 103-104.	0.3	1
62	The potential role of cardiac resynchronization therapy in acute heart failure syndromes. <i>Heart Failure Reviews</i> , 2011, 16, 481-490.	1.7	10
63	The potential application of electrophysiology diagnostics and therapeutics in acute heart failure syndromes. <i>Heart Failure Reviews</i> , 2011, 16, 437-439.	1.7	3
64	Pivotal trials of cardiac resynchronization therapy: evolution to therapy in mild heart failure. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2011, 31, 61-68.	0.6	6
65	Cardiac Resynchronization Therapy in Patients with Mild Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 331-340.	1.3	10
66	Cardiac Resynchronization in Mild Heart Failure: All Issues Resolved?. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 281-283.	1.3	1
73	Successful Percutaneous Cardiac Resynchronization Despite an Occlusive Thebesian Valve. <i>Pediatric Cardiology</i> , 2011, 32, 1223-1227.	0.6	10
74	Current Concepts in Pacing 2010â€“2011: The Right and Wrong Way to Pace. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2011, 13, 370-384.	0.4	3
75	New Paradigms in the Prevention of Sudden Cardiac Arrest and Heart Failure Treatment. <i>Current Cardiology Reports</i> , 2011, 13, 377-86.	1.3	1
76	Indications for Implantable Cardioverter-Defibrillator Placement in Ischemic Cardiomyopathy and after Myocardial Infarction. <i>Current Heart Failure Reports</i> , 2011, 8, 252-259.	1.3	4
77	Iron Deficiency in Community-Dwelling US Adults With Self-Reported Heart Failure in the National Health and Nutrition Examination Survey III. <i>Circulation: Heart Failure</i> , 2011, 4, 599-606.	1.6	84
78	Highlights of the latest clinical trials from the 2010 Scientific Sessions of the American Heart Association. <i>Future Cardiology</i> , 2011, 7, 163-167.	0.5	0
79	Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. <i>European Heart Journal</i> , 2011, 32, 1720-1729.	1.0	107
80	Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. <i>Cmaj</i> , 2011, 183, 421-429.	0.9	112
82	Cardiac-Resynchronization Therapy. <i>New England Journal of Medicine</i> , 2011, 364, 1277-1278.	13.9	0
83	New challenges in blood pressure goals and assessment. <i>Nature Reviews Cardiology</i> , 2011, 8, 73-75.	6.1	11

#	ARTICLE	IF	CITATIONS
85	Recent Advances in Cardiac Resynchronization Therapy. <i>Postgraduate Medicine</i> , 2011, 123, 18-26.	0.9	5
87	The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. <i>European Journal of Heart Failure</i> , 2011, 13, 917-924.	2.9	11
89	Heart failure highlights in 2010. <i>European Journal of Heart Failure</i> , 2011, 13, 358-363.	2.9	6
90	Cardiac resynchronization therapy for mild-to-moderate heart failure. <i>Expert Review of Medical Devices</i> , 2011, 8, 313-317.	1.4	5
91	Disease Pathways and Novel Therapeutic Targets in Hypertrophic Cardiomyopathy. <i>Circulation Research</i> , 2011, 109, 86-96.	2.0	153
92	Almanac 2011: heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Heart</i> , 2011, 97, 1643-1649.	1.2	2
93	Dyssynchrony, Contractile Function, and Response to Cardiac Resynchronization Therapy. <i>Circulation: Heart Failure</i> , 2011, 4, 433-440.	1.6	71
94	Impact of QRS Duration on Clinical Event Reduction With Cardiac Resynchronization Therapy. <i>Archives of Internal Medicine</i> , 2011, 171, 1454.	4.3	255
95	Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms. <i>Evidence-Based Medicine</i> , 2011, 16, 138-139.	0.6	0
96	A Prospective Pilot Study to Evaluate the Relationship Between Acute Change in Left Ventricular Synchrony After Cardiac Resynchronization Therapy and Patient Outcome Using a Single-Injection Gated SPECT Protocol. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 532-539.	1.3	92
97	Almanac 2011: cardiac arrhythmias and pacing. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Heart</i> , 2011, 97, 1734-1743.	1.2	0
98	Left Ventricular Versus Simultaneous Biventricular Pacing in Patients With Heart Failure and a QRS Complex $\geq 120$ Milliseconds. <i>Circulation</i> , 2011, 124, 2874-2881.	1.6	129
99	The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. <i>European Heart Journal</i> , 2011, 32, 2516-2524.	1.0	305
100	Adding CRT to ICD improves outcomes in patients with NYHA class II and III heart failure. <i>Nature Reviews Cardiology</i> , 2011, 8, 4-4.	6.1	1
101	One step forward, two steps back. <i>Nature Reviews Cardiology</i> , 2011, 8, 72-73.	6.1	6
102	Cardiac resynchronization therapy: from treatment to prevention. <i>European Heart Journal</i> , 2011, 32, 1580-1582.	1.0	7
103	Clinical course and outcome of patients enrolled in US and non-US centres in MADIT-CRT. <i>European Heart Journal</i> , 2011, 32, 2697-2704.	1.0	10
104	The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume. <i>Europace</i> , 2011, 13, 1445-1453.	0.7	27

#	ARTICLE	IF	CITATIONS
105	Long-Term Complications Related to Biventricular Defibrillator Implantation. <i>Circulation</i> , 2011, 123, 2526-2535.	1.6	80
106	Cardiac resynchronization therapy in mildly symptomatic heart failure: the earlier the better. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1147-1153.	0.6	0
107	Atrial fibrillation in elderly patients with heart failure: convergence of two cardiovascular epidemics in the 21st Century. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 903-912.	0.6	1
108	Sprint Fidelis Lead Fractures in Patients With Cardiac Resynchronization Therapy Devices. <i>Circulation</i> , 2012, 126, 2928-2934.	1.6	20
109	Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?. <i>Scientifica</i> , 2012, 2012, 1-16.	0.6	7
110	Cardiac resynchronisation therapy reduces mortality in patients with heart failure but questions remain. <i>Evidence-Based Medicine</i> , 2012, 17, 42-43.	0.6	0
111	Atrioventricular Nodal Ablation in Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 68-76.	2.1	84
112	Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2012, 5, 566-570.	1.6	155
113	A Practical Approach to the Difficult-to-Wean Patient. <i>Journal of the Intensive Care Society</i> , 2012, 13, 327-331.	1.1	3
114	CRT-D Therapy in Patients with Decompensated NYHA Class-Four CHF. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-4.	0.5	2
115	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	1.0	5,233
116	Recent advances in the management of chronic heart failure. <i>Current Opinion in Cardiology</i> , 2012, 27, 161-168.	0.8	9
117	Anesthetic Management of Electrophysiological Procedures for Heart Failure. <i>International Anesthesiology Clinics</i> , 2012, 50, 22-42.	0.3	4
118	Use of Primary Prevention Implantable Cardioverter-Defibrillators in a Population-Based Cohort Is Associated With a Significant Survival Benefit. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 706-713.	2.1	29
120	Interventions to decrease the morbidity and mortality associated with implantable cardioverter-defibrillator shocks. <i>Current Opinion in Critical Care</i> , 2012, 18, 432-437.	1.6	7
121	Cardiac resynchronization therapy. <i>Current Opinion in Cardiology</i> , 2012, 27, 137-142.	0.8	0
122	Use of biomarkers to guide outpatient therapy of heart failure. <i>Current Opinion in Cardiology</i> , 2012, 27, 661-668.	0.8	19
123	Improvement in Coronary Blood Flow Velocity With Acute Biventricular Pacing Is Predominantly Due to an Increase in a Diastolic Backward-Travelling Decompression (Suction) Wave. <i>Circulation</i> , 2012, 126, 1334-1344.	1.6	37

#	ARTICLE	IF	CITATIONS
124	The relationship of QRS morphology and mechanical dyssynchrony to long-term outcome following cardiac resynchronization therapy. <i>European Heart Journal</i> , 2012, 33, 2680-2691.	1.0	87
125	Sex-related differences in patients' responses to heart failure therapy. <i>Nature Reviews Cardiology</i> , 2012, 9, 234-242.	6.1	31
126	The European CRT Survey: 1 year (9â€“15 months) followâ€“up results. <i>European Journal of Heart Failure</i> , 2012, 14, 61-73.	2.9	87
127	Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVERses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. <i>European Journal of Heart Failure</i> , 2012, 14, 1420-1428.	2.9	37
128	Longâ€“term mortality with cardiac resynchronization therapy in the Cardiac Resynchronizationâ€“Heart Failure (CAREâ€“HF) trial. <i>European Journal of Heart Failure</i> , 2012, 14, 628-634.	2.9	121
129	Atrioventricular nodal ablation in atrial fibrillation: a metaâ€“analysis of biventricular vs. right ventricular pacing mode. <i>European Journal of Heart Failure</i> , 2012, 14, 661-667.	2.9	59
130	Preventive cardiac resynchronisation therapy. <i>Heart</i> , 2012, 98, 508-515.	1.2	0
131	Cost-effectiveness of cardiac resynchronisation therapy. <i>Heart</i> , 2012, 98, 1828-1836.	1.2	31
133	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Circulation</i> , 2012, 126, 1784-1800.	1.6	321
134	Subcutaneous Implantable Cardioverter Defibrillator. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 587-593.	2.1	50
135	Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2012, 126, 2402-2407.	1.6	66
136	Predictors of Sustained Ventricular Arrhythmias in Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 762-772.	2.1	17
137	Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. <i>Europace</i> , 2012, 14, 1490-1497.	0.7	78
138	The Atria Are Fibrillating. <i>Circulation: Heart Failure</i> , 2012, 5, 547-549.	1.6	2
139	Cardiology in Family Practice. , 2012, , .		3
140	COST-EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION THERAPY: PERSPECTIVE FROM ARGENTINA. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 429-435.	0.2	7
141	Who needs a transplant and when?. <i>Current Opinion in Organ Transplantation</i> , 2012, 17, 531-539.	0.8	0
142	Left ventricular lead position for cardiac resynchronization: a comprehensive cinegraphic, echocardiographic, clinical, and survival analysis. <i>Europace</i> , 2012, 14, 1139-1147.	0.7	54



#	ARTICLE	IF	CITATIONS
143	Biventricular pacing: current trends and future strategies. <i>European Heart Journal</i> , 2012, 33, 305-313.	1.0	26
144	Baseline delayed left ventricular activation predicts long-term clinical outcome in cardiac resynchronization therapy recipients. <i>Europace</i> , 2012, 14, 358-364.	0.7	9
145	First prospective, multi-centre clinical experience with a novel left ventricular quadripolar lead. <i>Europace</i> , 2012, 14, 365-372.	0.7	79
146	Women have better long-term prognosis than men after cardiac resynchronization therapy. <i>Europace</i> , 2012, 14, 1148-1155.	0.7	69
147	Small left atrium and mild mitral regurgitation predict super-response to cardiac resynchronization therapy. <i>Europace</i> , 2012, 14, 1608-1614.	0.7	24
148	Independent predictors of mortality in patients with advanced heart failure treated by cardiac resynchronization therapy. <i>Europace</i> , 2012, 14, 1596-1601.	0.7	26
149	Cramping of temporary pacemaker lead via femoral vein during laparoscopic nephrectomy: a rare condition. <i>Europace</i> , 2012, 14, 1539-1539.	0.7	0
150	Approach to cardiac resynchronization therapy. <i>Europace</i> , 2012, 14, 1359-1362.	0.7	6
151	Effect of cardiac resynchronization therapy on quality of life: the best gets the least. <i>Europace</i> , 2012, 14, 1537-1539.	0.7	4
152	Challenges in cardiac resynchronization therapy-defibrillator upgrade in a patient with right pneumonectomy. <i>Europace</i> , 2012, 14, 1497-1497.	0.7	0
153	Greater response to cardiac resynchronization therapy in patients with true complete left bundle branch block: a PREDICT substudy. <i>Europace</i> , 2012, 14, 690-695.	0.7	33
154	Advancing Cardiovascular Research. <i>Chest</i> , 2012, 141, 500-505.	0.4	25
155	Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy. <i>Yearbook of Cardiology</i> , 2012, 2012, 306-309.	0.0	0
156	Mortality Reduction of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Heart Failure: An Updated Meta-Analysis. Does Recent Evidence Change the Standard of Care?. <i>Yearbook of Cardiology</i> , 2012, 2012, 303-306.	0.0	0
157	Mortality Reduction of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Heart Failure: An Updated Meta-Analysis. Does Recent Evidence Change the Standard of Care?. <i>Yearbook of Medicine</i> , 2012, 2012, 347-350.	0.1	0
158	Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: A systematic review. <i>Yearbook of Cardiology</i> , 2012, 2012, 296-299.	0.0	0
159	Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. <i>Yearbook of Cardiology</i> , 2012, 2012, 309-312.	0.0	0
160	Prognostic Significance of Long-Period Heart Rate Rhythms in Chronic Heart Failure. <i>Circulation Journal</i> , 2012, 76, 2124-2129.	0.7	4

#	ARTICLE	IF	CITATIONS
161	Clinical Efficacy of Cardiac Resynchronization Therapy With an Implantable Defibrillator in a Japanese Population. <i>Circulation Journal</i> , 2012, 76, 1911-1919.	0.7	23
162	Imaging for Planning of Cardiac Resynchronization Therapy. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 93-110.	2.3	32
163	Cardiac Venous Left Ventricular Lead Removal and Reimplantation Following Device Infection: A Large Single-Center Experience. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1213-1216.	0.8	26
164	Cardiac resynchronization therapy: a breakthrough in heart failure management. <i>Journal of Internal Medicine</i> , 2012, 272, 330-343.	2.7	11
165	Multimodality imaging in interventional cardiology. <i>Nature Reviews Cardiology</i> , 2012, 9, 333-346.	6.1	39
166	Prophylactic implantable defibrillators in dilated cardiomyopathy. <i>Herz</i> , 2012, 37, 859-868.	0.4	3
167	The determinants of clinical outcome and clinical response to CRT are not the same. <i>Heart Failure Reviews</i> , 2012, 17, 755-766.	1.7	21
168	A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy. <i>Heart Failure Reviews</i> , 2012, 17, 767-775.	1.7	9
169	Increasing knowledge and changing views in cardiac resynchronization therapy. <i>Heart Failure Reviews</i> , 2012, 17, 721-725.	1.7	2
170	How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection?. <i>Heart Failure Reviews</i> , 2012, 17, 791-802.	1.7	1
171	Cardiac dysfunction in the CABG patient. <i>Current Opinion in Pharmacology</i> , 2012, 12, 166-171.	1.7	18
172	2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, e127-e145.	0.4	44
173	How to Assess the Nonresponder to Cardiac Resynchronization Therapy—A Comprehensive Stepwise Approach. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2012, 65, 504-510.	0.4	4
174	Almanac 2011: Cardiac arrhythmias and pacing. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Revista Portuguesa De Cardiologia (English)</i> Tj ETQq1 1 0.784814 rgBTqOverlod		
175	Comentarios a la guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 874-878.	0.6	32
176	Comments on the ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2012, 65, 874-878.	0.4	7
177	Terapia de resincronización cardiaca. Indicaciones y contraindicaciones. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 843-849.	0.6	9
178	Contemporary and future trends in cardiac resynchronization therapy to enhance response. <i>Heart Rhythm</i> , 2012, 9, S27-S35.	0.3	20

#	ARTICLE	IF	CITATIONS
179	Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: Insights from the SMART-AV multicenter trial. <i>Heart Rhythm</i> , 2012, 9, 736-741.	0.3	42
180	Multispecialty approach: The need for heart failure disease management for refining cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2012, 9, S45-S50.	0.3	7
181	Should a Patient with Severe Left Ventricular Dysfunction, Congestive Heart Failure, and Right Bundle Branch Block QRS Receive Cardiac Resynchronization Therapy?. <i>Cardiac Electrophysiology Clinics</i> , 2012, 4, 161-168.	0.7	0
182	Baseline functional capacity and the benefit of cardiac resynchronization therapy in patients with mildly symptomatic heart failure enrolled in MADIT-CRT. <i>Heart Rhythm</i> , 2012, 9, 1454-1459.	0.3	6
183	Análisis transversal de la resincronización cardíaca en España. Indicaciones, técnicas de implante, optimización y seguimiento. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 826-834.	0.6	3
184	The Genetics of Cardiac Disease Associated with Sudden Cardiac Death. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 424-436.	1.2	4
185	Renin-angiotensin blockade as primary prevention during right ventricular pacing: An alternative strategy in managing cardiac dyssynchrony. <i>Heart Rhythm</i> , 2012, 9, 511-512.	0.3	0
186	Almanac 2011: Cardiac arrhythmias and pacing. The national society journals present selected research that has driven recent advances in clinical cardiology. <i>Revista Portuguesa De Cardiologia</i> , 2012, 31, 57-69.	0.2	0
187	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Heart Rhythm</i> , 2012, 9, 1737-1753.	0.3	131
188	Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. <i>Europace</i> , 2012, 14, 1602-1607.	0.7	31
189	Assessing reverse remodeling in heart failure patients treated with cardiac resynchronization therapy and its impact on prognosis. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1437-1448.	0.6	2
191	Cross-sectional Study of Cardiac Resynchronization Therapy in Spain. Indications, Implant Techniques, Optimization and Follow-up. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2012, 65, 826-834.	0.4	1
192	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
194	Evaluación del paciente que no responde al tratamiento de resincronización cardíaca: un enfoque escalonado completo. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 504-510.	0.6	15
195	Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure. <i>Circulation</i> , 2012, 126, 822-829.	1.6	279
196	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (FAE) of the ESC and the Heart		

#	ARTICLE	IF	CITATIONS
199	Performance of the Seattle Heart Failure Model in Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2012, 110, 398-402.	0.7	21
200	Long-term outcome after Cardiac Resynchronization Therapy: A nationwide database. <i>International Journal of Cardiology</i> , 2012, 155, 492-493.	0.8	11
201	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 94-106.	0.7	93
202	Comparison of Cardiac Resynchronization Therapy Outcomes in Patients With New York Heart Association Functional Class I/II Versus III/IV Heart Failure. <i>Journal of Cardiac Failure</i> , 2012, 18, 373-378.	0.7	12
203	Reasons for Loss of Cardiac Resynchronization Therapy Pacing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 884-888.	2.1	91
204	QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 27.	0.7	5
206	Past, present and future of cardiac resynchronization. <i>Archives of Cardiovascular Diseases</i> , 2012, 105, 291-299.	0.7	8
207	The Year in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 60, 359-368.	1.2	19
208	Differential Response to Cardiac Resynchronization Therapy and Clinical Outcomes According to QRS Morphology and QRS Duration. <i>Journal of the American College of Cardiology</i> , 2012, 60, 592-598.	1.2	93
209	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1297-1313.	1.2	335
210	MR Cine DENSE Dyssynchrony Parameters for the Evaluation of Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 789-797.	2.3	36
211	Atrioventricular delay programming in cardiac resynchronization therapy devices: fixed or adaptive?. <i>Journal of Electrocardiology</i> , 2012, 45, 783-786.	0.4	1
212	Left bundle-branch block and a left-sided accessory pathway: physiologic cardiac synchronization?. <i>Journal of Electrocardiology</i> , 2012, 45, 525-527.	0.4	2
213	Differentiation between left bundle branch block and left ventricular hypertrophy: Implications for cardiac resynchronization therapy. <i>Journal of Electrocardiology</i> , 2012, 45, 635-639.	0.4	31
214	Comorbidity Significantly Affects Clinical Outcome After Cardiac Resynchronization Therapy Regardless of Ventricular Remodeling. <i>Journal of Cardiac Failure</i> , 2012, 18, 845-853.	0.7	35
215	A case of biventricular pacing with a spike on T-wave caused by the algorithm maintaining biventricular pacing rate. <i>Journal of Arrhythmia</i> , 2012, 28, 56-60.	0.5	1
216	Device therapy in Chagas disease heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1307-1317.	0.6	10
217	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. <i>Heart Rhythm</i> , 2012, 9, 1524-1576.	0.3	300

#	ARTICLE	IF	CITATIONS
218	The Subcutaneous Defibrillator. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 550-557.	0.4	7
219	Acute hemodynamic response to biventricular pacing in heart failure patients with narrow, moderately, and severely prolonged QRS duration. Heart Rhythm, 2012, 9, 1247-1250.	0.3	16
220	Effect of Cardiac Resynchronization Therapy on the Risk of First and Recurrent Ventricular Tachyarrhythmic Events in MADIT-CRT. Journal of the American College of Cardiology, 2012, 60, 1809-1816.	1.2	65
221	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	0.6	31
222	Cardiac Resynchronization Therapy. Indications and Contraindications. Revista Espanola De Cardiologia (English Ed ), 2012, 65, 843-849.	0.4	8
223	Expanding Indications for Resynchronization Therapy. Current Cardiology Reports, 2012, 14, 540-546.	1.3	3
224	Implantable Cardiovascular Sensors and Computers: Interventional Heart Failure Strategies. Current Cardiology Reports, 2012, 14, 611-618.	1.3	8
225	Cardiac resynchronization therapy for prevention of heart failure events in elderly patients with left ventricular dysfunction. Expert Review of Cardiovascular Therapy, 2012, 10, 1319-1327.	0.6	5
226	Cardiac resynchronization therapy (CRT): Clinical trials, guidelines, and target populations. Heart Rhythm, 2012, 9, S3-S13.	0.3	93
227	Device Therapy for Systolic Ventricular Failure. , 2012, , 721-737.		0
228	SCN5A Mutations in Brugada Syndrome Are Associated with Increased Cardiac Dimensions and Reduced Contractility. PLoS ONE, 2012, 7, e42037.	1.1	66
229	Mensagem do Editor. Arquivos Brasileiros De Cardiologia, 2012, 99, 575-575.	0.3	32
230	Cardiac Electrical System Involvement in Alström Syndrome: Uncommon Causes of Dilated Cardiomyopathies. Neurology International, 2012, 2, e2.	0.2	2
232	Acute and Chronic Response to CRT in Narrow QRS Patients. Journal of Cardiovascular Translational Research, 2012, 5, 232-241.	1.1	22
233	Implantable cardioverter defibrillator harm?. Europace, 2012, 14, 1087-1093.	0.7	10
234	The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure. Heart Failure Reviews, 2012, 17, 345-353.	1.7	19
235	Systolic heart failure in the elderly: optimizing medical management. Heart Failure Reviews, 2012, 17, 563-571.	1.7	14
236	Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Failure Reviews, 2012, 17, 133-149.	1.7	74

#	ARTICLE	IF	CITATIONS
237	Electrical devices for left ventricular dysfunction and heart failure: do we need revised guidelines?. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 197-204.	0.6	6
238	Transcriptome, Proteome, and Metabolome in Dyssynchronous Heart Failure and CRT. Journal of Cardiovascular Translational Research, 2012, 5, 180-187.	1.1	18
239	Electrical and Mechanical Ventricular Activation During Left Bundle Branch Block and Resynchronization. Journal of Cardiovascular Translational Research, 2012, 5, 117-126.	1.1	41
240	Clinical, Laboratory, and Pacing Predictors of CRT Response. Journal of Cardiovascular Translational Research, 2012, 5, 196-212.	1.1	22
241	Cardiac dyssynchrony: We have the tools. It is time to use them. Journal of Nuclear Cardiology, 2012, 19, 420-423.	1.4	1
242	Left ventricular endocardial pacing in cardiac resynchronisation therapy: Moving from bench to bedside. Netherlands Heart Journal, 2012, 20, 118-124.	0.3	18
244	Rates of Upgrade of ICD Recipients to CRT in Clinical Practice and the Potential Impact of the More Liberal Use of CRT at Initial Implant. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 73-80.	0.5	22
245	Impact of Mitral Regurgitation on the Outcome of Patients Treated with CRT: Data from the InSync ICD Italian Registry. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 146-154.	0.5	17
246	Cardiac Resynchronization Therapy with or Without Anatomical Reverse Remodeling Does Not Affect Defibrillation Threshold. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 416-421.	0.5	1
247	The Benefit of Cardiac Resynchronization Therapy and QRS Duration: A Meta-Analysis. Journal of Cardiovascular Electrophysiology, 2012, 23, 163-168.	0.8	97
248	Rethinking QRS Duration as an Indication for CRT. Journal of Cardiovascular Electrophysiology, 2012, 23, 169-171.	0.8	6
249	Optimization of Cardiac Resynchronization Therapy: Importance of Programmed Parameters. Journal of Cardiovascular Electrophysiology, 2012, 23, 110-118.	0.8	27
250	Almanac 2011: Heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. Egyptian Heart Journal, 2012, 64, 51-58.	0.4	0
251	Almanac 2011: Cardiac arrhythmias and pacing. The national society journals present selected research that has driven recent advances in clinical cardiology. Egyptian Heart Journal, 2012, 64, 25-37.	0.4	0
252	Extraordinarily Favorable Left Ventricular Reverse Remodeling through Long-Term Cardiac Resynchronization: Super-Response to Cardiac Resynchronization. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 870-876.	0.5	11
253	Implantation Feasibility, Procedure-Related Adverse Events and Lead Performance During 1-Year Follow-Up in Patients Undergoing Triple-Site Cardiac Resynchronization Therapy: A Substudy of TRUST CRT Randomized Trial. Journal of Cardiovascular Electrophysiology, 2012, 23, 1228-1236.	0.8	43
254	Reverse Electrical Remodeling by Cardiac Resynchronization Therapy: Prevalence and Clinical Impact. Journal of Cardiovascular Electrophysiology, 2012, 23, 1219-1227.	0.8	29
255	A Randomized-Controlled Pilot Study Comparing ICD Implantation with and Without Intraoperative Defibrillation Testing in Patients with Heart Failure and Severe Left Ventricular Dysfunction: A Substudy of the RAFT Trial. Journal of Cardiovascular Electrophysiology, 2012, 23, 1313-1316.	0.8	35



#	ARTICLE	IF	CITATIONS
256	Atrial Support Pacing in Heart Failure: Results from the Multicenter PEGASUS CRT Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1317-1325.	0.8	39
258	The Emerging Role of Cardiac Resynchronization Therapy in Milder Heart Failure: Are We Implanting Too Late for Response?. <i>Current Heart Failure Reports</i> , 2012, 9, 51-56.	1.3	0
260	Animal Models of Dyssynchrony. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 135-145.	1.1	32
261	Empiric versus imaging guided left ventricular lead placement in cardiac resynchronization therapy (ImagingCRT): study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 113.	0.7	28
262	Tratamiento de la insuficiencia cardiaca cr�nica. <i>Medicine</i> , 2013, 11, 2146-2156.	0.0	0
263	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1495-1539.	1.2	276
264	Active fixation mechanism complicates coronary sinus lead extraction and limits subsequent reimplantation targets. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 36, 81-86.	0.6	23
265	Is Cardiac Resynchronization Therapy an Antiarrhythmic Therapy for Atrial Fibrillation? A Systematic Review and Meta-Analysis. <i>Current Cardiology Reports</i> , 2013, 15, 330.	1.3	30
268	The amount of viable and dyssynchronous myocardium is associated with response to cardiac resynchronization therapy: initial clinical results using multiparametric ECG-gated [18F]FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1876-1883.	3.3	26
269	One-year outcome after CRT implantation in NYHA class IV in comparison to NYHA class III patients. <i>Clinical Research in Cardiology</i> , 2013, 102, 505-511.	1.5	9
271	Right, But Not Left, Bundle Branch Block Is Associated With Large Anteroseptal Scar. <i>Journal of the American College of Cardiology</i> , 2013, 62, 959-967.	1.2	46
272	The Influence of Left Ventricular Ejection Fraction on the Effectiveness of Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2013, 61, 936-944.	1.2	86
273	Survival of Patients With Biventricular Devices After Device Infection, Extraction, and Reimplantation. <i>JACC: Heart Failure</i> , 2013, 1, 508-513.	1.9	21
274	Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1346-1360.	0.8	22
275	Device Therapy in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 945-947.	1.2	8
276	Heart failure therapy in patients with coronary artery disease. <i>Current Opinion in Pharmacology</i> , 2013, 13, 205-209.	1.7	16
277	Usefulness and Consequences of Cardiac Resynchronization Therapy in Dialysis-Dependent Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 1625-1631.	0.7	10
278	Loss of Continuous Biventricular Pacing in Cardiac Resynchronization Therapy Patients: Incidence, Causes, and Outcomes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 377-383.	0.4	4

#	ARTICLE	IF	CITATIONS
279	Quantification of Survival Gain From Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2406-2413.	1.2	18
280	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Circulation</i> , 2013, 128, e240-327.	1.6	2,335
281	Case Selection for Cardiac Resynchronization in Atrial Fibrillation. <i>Heart Failure Clinics</i> , 2013, 9, 461-474.	1.0	14
282	Revisiting diastolic filling time as mechanistic insight for response to cardiac resynchronization therapy. <i>Europace</i> , 2013, 15, 1747-1756.	0.7	21
283	The role of AV and VV optimization for CRT. <i>Journal of Arrhythmia</i> , 2013, 29, 153-161.	0.5	29
284	Surgical Treatment for Advanced Heart Failure. , 2013, , .		5
285	Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health system. <i>International Journal of Cardiology</i> , 2013, 163, 309-315.	0.8	27
286	Association between QRS duration and outcome with cardiac resynchronization therapy: A systematic review and meta-analysis. <i>Journal of Electrocardiology</i> , 2013, 46, 147-155.	0.4	49
287	Almanac 2013: heart failure. <i>Heart</i> , 2013, 99, 1562-1566.	1.2	4
288	Rate, causes, and impact on patient outcome of implantable device complications requiring surgical revision: large population survey from two centres in Italy. <i>Europace</i> , 2013, 15, 531-540.	0.7	118
289	Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVERses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. <i>European Heart Journal</i> , 2013, 34, 2592-2599.	1.0	150
290	Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry. <i>Europace</i> , 2013, 15, 1273-1279.	0.7	45
291	The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients. <i>Europace</i> , 2013, 15, 992-1001.	0.7	18
292	Localization of myocardial scar in patients with cardiomyopathy and left bundle branch block using electrocardiographic Selvester QRS scoring. <i>Journal of Electrocardiology</i> , 2013, 46, 249-255.	0.4	17
293	Optimisation of cardiac resynchronisation therapy during exercise. <i>Netherlands Heart Journal</i> , 2013, 21, 456-457.	0.3	1
295	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex. <i>New England Journal of Medicine</i> , 2013, 369, 1395-1405.	13.9	688
296	Heart Failure—Associated Hospitalizations in the United States. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1259-1267.	1.2	323
298	Gender—Related Safety and Efficacy of Cardiac Resynchronization Therapy. <i>Clinical Cardiology</i> , 2013, 36, 683-690.	0.7	23



#	ARTICLE	IF	CITATIONS
299	The Gender Paradox among Patients with Implantable Cardioverter-Defibrillators: A Propensity-Matched Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 878-884.	0.5	23
300	An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. <i>European Heart Journal</i> , 2013, 34, 3547-3556.	1.0	410
301	Implications of Left Bundle Branch Block in Patient Treatment. <i>American Journal of Cardiology</i> , 2013, 111, 291-300.	0.7	50
302	Validation of Seattle Heart Failure Model for mortality risk prediction in patients treated with cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2013, 15, 211-220.	2.9	29
303	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Journal of the American College of Cardiology</i> , 2013, 61, e6-e75.	1.2	736
304	The Year in Cardiology 2012: heart failure. <i>European Heart Journal</i> , 2013, 34, 499-502.	1.0	0
305	The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 168-181.	0.8	176
306	Cost-Effectiveness of Cardiac Resynchronization Therapy in the MADIT-CRT Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 66-74.	0.8	50
307	Electrical Delay in Apically Positioned Left Ventricular Leads and Clinical Outcome After Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 182-187.	0.8	16
308	Baseline vectorcardiography as a predictor of invasively determined acute hemodynamic response to cardiac resynchronization therapy. <i>Clinical Research in Cardiology</i> , 2013, 102, 129-138.	1.5	6
309	2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR Appropriate Utilization of Cardiovascular Imaging in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2207-2231.	1.2	134
310	Dyssynchrony and the Risk of Ventricular Arrhythmias. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 432-444.	2.3	72
311	Effectiveness of Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy in Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 59-77.	1.0	7
312	Left Bundle Branch Block Predicts Better Survival in Women Than Men Receiving Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2013, 1, 237-244.	1.9	45
313	Effect on Cardiac Function of Cardiac Resynchronization Therapy in Patients With Right Bundle Branch Block (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac) <i>Tj ETQq0 0 0 rgBT /Overlock 10 150 177 T</i>	1.0	15
314	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. <i>International Journal of Cardiology</i> , 2013, 167, 1772-1782.	0.8	67
315	Prognostic Value of QRS Duration After Transcatheter Aortic Valve Implantation for Aortic Stenosis Using the CoreValve. <i>American Journal of Cardiology</i> , 2013, 111, 1778-1783.	0.7	20
316	Effects of cardiac resynchronization therapy on left ventricular mass and wall thickness in mild heart failure patients in MADIT-CRT. <i>Heart Rhythm</i> , 2013, 10, 354-360.	0.3	7

#	ARTICLE	IF	CITATIONS
317	Noninvasive Electrocardiographic Mapping to Improve Patient Selection for Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2435-2443.	1.2	178
318	Heart failure services in the United Kingdom: Rethinking the machine bureaucracy. <i>International Journal of Cardiology</i> , 2013, 162, 143-148.	0.8	8
319	Cardiac resynchronization therapy: Forget QRS duration but do not forget QRS morphology. <i>Journal of Electrocardiology</i> , 2013, 46, 145-146.	0.4	3
320	QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2013, 10, 55-60.	0.3	43
321	Short-term reduction in intrinsic heart rate during biventricular pacing after cardiac surgery: A substudy of a randomized clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 1494-1500.	0.4	5
322	Strategies to Prevent Postdischarge Adverse Events Among Hospitalized Patients with Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 303-320.	1.0	12
323	Pacemaker dependency after transcatheter aortic valve implantation with the self-expanding Medtronic CoreValve System. <i>International Journal of Cardiology</i> , 2013, 168, 1269-1273.	0.8	105
324	Impact of the right ventricular lead position on clinical outcome and on the incidence of ventricular tachyarrhythmias in patients with CRT-D. <i>Heart Rhythm</i> , 2013, 10, 1770-1777.	0.3	39
325	Optimal Utilization and Management of Implanted Cardiac Rhythm Devices in Patients Hospitalized for Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 321-330.	1.0	0
326	Detection of regional low myocardial perfusion helps predict a response to cardiac resynchronization therapy in patients with non-ischemic cardiomyopathy: Results of the Find Index by Nuclear Imaging for Dyssynchrony (FIND) study. <i>Journal of Arrhythmia</i> , 2013, 29, 180-186.	0.5	1
327	Pacing transmural scar tissue reduces left ventricle reverse remodeling after cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2013, 167, 94-101.	0.8	22
328	Acute Effects of Withdrawal of Cardiac Resynchronization Therapy on Left and Right Ventricular Function, Dyssynchrony, and Contractile Function in Patients With New York Heart Association Functional Class I/II Heart Failure: MADIT-CRT. <i>Journal of Cardiac Failure</i> , 2013, 19, 149-155.	0.7	16
329	Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRT. <i>Heart Rhythm</i> , 2013, 10, 1136-1143.	0.3	25
330	Clinical significance of ventricular tachyarrhythmias in patients treated with CRT-D. <i>Heart Rhythm</i> , 2013, 10, 943-950.	0.3	4
331	Current status of cardiac resynchronization therapy with defibrillators and factors influencing its prognosis in Japan. <i>Journal of Arrhythmia</i> , 2013, 29, 168-174.	0.5	11
332	VT begets VT and other bad stuff in patients treated with CRT-D. <i>Heart Rhythm</i> , 2013, 10, 951-952.	0.3	0
333	In silico study of the haemodynamic effects induced by mechanical ventilation and biventricular pacemaker. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 110, 519-527.	2.6	6
335	Differing effects of cardiac resynchronization therapy on long-term mortality in patient subgroups of MADIT-CRT defined by baseline conduction and 1-year post-treatment left ventricular remodeling. <i>Heart Rhythm</i> , 2013, 10, 366-373.	0.3	14

#	ARTICLE	IF	CITATIONS
337	Does cardiac resynchronization therapy benefit patients with ischemic and non-ischemic cardiomyopathy similarly?. <i>International Journal of Cardiology</i> , 2013, 168, 4378-4380.	0.8	8
338	Causes and prevention of sudden cardiac death in the elderly. <i>Nature Reviews Cardiology</i> , 2013, 10, 135-142.	6.1	39
339	Anatomy of the Coronary Sinus and Epicardial Coronary Venous System in 620 Hearts: An Electrophysiology Perspective. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 1-6.	0.8	58
340	Unidentified Candidates for Cardiac Resynchronization Therapy: Guideline Adherence in a Large Academic Outpatient Clinic in the Netherlands. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 69-75.	0.5	1
341	Devices in the management of advanced, chronic heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 98-110.	6.1	56
342	Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection. <i>Canadian Journal of Cardiology</i> , 2013, 29, 182-195.	0.8	53
343	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, e147-e239.	1.2	7,017
344	Left ventricular mechanical dyssynchrony by cardiac magnetic resonance is greater in patients with strict vs nonstrict electrocardiogram criteria for left bundle-branch block. <i>American Heart Journal</i> , 2013, 165, 956-963.	1.2	28
345	Treatment of Congestive Heart Failure. , 2013, , 347-360.		1
346	Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation. <i>New England Journal of Medicine</i> , 2013, 368, 2084-2093.	13.9	482
347	True complete left bundle branch block morphology strongly predicts good response to cardiac resynchronization therapy. <i>Europace</i> , 2013, 15, 1499-1506.	0.7	76
348	Cardiac Resynchronization Therapy: Do Patient Selection and Implant Practice Vary Depending on the Volume a Center Handles?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 863-871.	0.5	1
349	Cost-effectiveness of heart failure therapies. <i>Nature Reviews Cardiology</i> , 2013, 10, 338-354.	6.1	66
350	Cardiac Resynchronization Therapy. <i>Circulation</i> , 2013, 128, 2407-2418.	1.6	116
351	Impact of Ejection Fraction on the Clinical Response to Cardiac Resynchronization Therapy in Mild Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 1180-1189.	1.6	27
352	ECG "Still the Best for Selecting Patients for CRT. <i>New England Journal of Medicine</i> , 2013, 369, 1463-1464.	13.9	9
353	Cardiac resynchronization therapy. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 265-270.	0.2	1
354	Clinical outcome after 1 year of cardiac resynchronisation therapy: national results from the European CRT survey. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 750-754.	1.0	0

#	ARTICLE	IF	CITATIONS
355	Echocardiographic Predictors of Reverse Remodeling After Cardiac Resynchronization Therapy and Subsequent Events. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 864-872.	1.3	37
356	Impact of clinical and echocardiographic response to cardiac resynchronization therapy on long-term survival. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 774-781.	0.5	49
357	Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. <i>Europace</i> , 2013, 15, 71-76.	0.7	64
358	Mortality and morbidity in cardiac resynchronization patients: impact of lead position, paced left ventricular QRS morphology and other characteristics on long-term outcome. <i>Europace</i> , 2013, 15, 258-265.	0.7	31
359	Acute haemodynamic comparison of multisite and biventricular pacing with a quadripolar left ventricular lead. <i>Europace</i> , 2013, 15, 984-991.	0.7	121
360	Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK. <i>Europace</i> , 2013, 15, 1601-1608.	0.7	49
361	Antiarrhythmic effect of cardiac resynchronization therapy with triple-site biventricular stimulation. <i>Europace</i> , 2013, 15, 1491-1498.	0.7	23
362	Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction. <i>Europace</i> , 2013, 15, 1609-1614.	0.7	31
363	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). <i>Europace</i> , 2013, 15, 1070-1118.	0.7	908
366	Cardiac Resynchronization Therapy in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1293-1303.	2.2	29
367	Cardiac resynchronization therapy: state of the art 2013. <i>European Heart Journal</i> , 2013, 34, 1396-1403.	1.0	66
368	Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon. <i>Europace</i> , 2013, 15, 1453-1462.	0.7	47
369	Left Ventricular Epicardial Electrograms Show Divergent Changes in Action Potential Duration in Responders and Nonresponders to Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 265-271.	2.1	14
370	Dilated Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 228-237.	2.1	93
371	Impact of QRS Morphology and Duration on Outcomes After Cardiac Resynchronization Therapy. <i>Circulation: Heart Failure</i> , 2013, 6, 1190-1198.	1.6	133
372	Mitral valve pathology in severely impaired left ventricles can be successfully managed using a right-sided minimally invasive surgical approach. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 44, e1-e7.	0.6	15
373	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. <i>Circulation</i> , 2013, 127, e283-352.	1.6	803
374	Cardiac Resynchronization Therapy MOdular REgistry. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 886-893.	0.6	18

#	ARTICLE	IF	CITATIONS
375	Brain Natriuretic Peptide and Cardiac Resynchronization Therapy in Patients With Mildly Symptomatic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 998-1004.	1.6	25
376	Resynchronization: Considering Device-Based Cardiac Therapy in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 615-621.	1.3	13
377	Influence of Pacing Site Characteristics on Response to Cardiac Resynchronization Therapy. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 542-550.	1.3	47
378	QRS Duration Criteria to Select Patients for Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 429-435.	2.1	5
379	Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2013, , 241-269.		1
380	Implantable Devices for the Management of Heart Failure. , 2013, , 270-280.		0
381	Role of Implantable Cardioverter-Defibrillators in Primary and Secondary Prevention of Sudden Cardiac Death. , 2013, , 396-407.		0
382	Follow-up of Patients With New Cardiovascular Implantable Electronic Devices. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 108-116.	2.1	38
383	Implantable Defibrillators Improve Survival in Patients With Mildly Symptomatic Heart Failure Receiving Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 1163-1168.	2.1	51
384	Narrow QRS Is Not the Right Substrate for Cardiac Resynchronization Therapy. <i>Circulation</i> , 2013, 127, 1093-1094.	1.6	3
385	Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. <i>Heart</i> , 2013, 99, 314-319.	1.2	16
386	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Circulation</i> , 2013, 128, 1810-1852.	1.6	2,807
387	Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors. <i>Europace</i> , 2013, 15, i40-i46.	0.7	36
388	Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians. <i>European Journal of Heart Failure</i> , 2013, 15, 203-210.	2.9	58
389	Clinical Characteristics, Mortality, Cardiac Hospitalization, and Ventricular Arrhythmias in Patients Undergoing CRT-D Implantation: Results of the ACTION-HF Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 173-181.	0.8	9
390	QRS Axis and the Benefit of Cardiac Resynchronization Therapy in Patients with Mildly Symptomatic Heart Failure Enrolled in MADIT-CRT. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 442-448.	0.8	24
391	Outcomes of Cardiac Resynchronization Therapy in the Elderly. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 664-672.	0.5	42
392	Complete atrioventricular block does not reduce long-term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2013, 15, 1412-1418.	2.9	20

#	ARTICLE	IF	CITATIONS
393	Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 877-884.	2.9	27
394	Impact of Using a Telescoping Support Catheter System for Left Ventricular Lead Placement on Implant Success and Procedure Time of Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 553-558.	0.5	20
395	QRS Duration Changes in Patients with Hypoplastic Left Heart Syndrome Undergoing Hybrid Palliation: Prehybrid to PostFontan. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 462-466.	0.5	4
396	Clinical, Echocardiographic, and Neurohormonal Response to Cardiac Resynchronization Therapy: Are They Interchangeable?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 1391-1401.	0.5	16
397	Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2013, 15, 1419-1428.	2.9	40
398	Long-term clinical response to cardiac resynchronisation therapy under a multidisciplinary model. <i>Internal Medicine Journal</i> , 2013, 43, 1216-1223.	0.5	1
399	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
400	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1044-1052.	2.9	22
401	More Bad News for Cardiac Resynchronization Therapy in Atrial Fibrillation Patients: What to Do?. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 1123-1124.	0.8	0
402	Cardiac Resynchronization Therapy in Patients with Atrial Fibrillation: A 2-Year Follow-Up Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 872-877.	0.5	6
403	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.	1.0	2,176
404	Cardiac Resynchronization Therapy in Patients With Heart Failure and a QRS Complex <120 Milliseconds. <i>Circulation</i> , 2013, 127, 873-881.	1.6	132
405	COST-EFFECTIVENESS ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH NYHA I AND NYHA II HEART FAILURE IN SPAIN. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 140-146.	0.2	5
406	Gender Difference in Coronary Sinus Anatomy and Left Ventricular Lead Pacing Parameters in Patients With Cardiac Resynchronization Therapy. <i>Circulation Journal</i> , 2013, 77, 1424-1429.	0.7	4
407	Potential Role of Biventricular Pacing Beyond Advanced Systolic Heart Failure. <i>Circulation Journal</i> , 2013, 77, 1364-1369.	0.7	13
408	Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011). <i>Circulation Journal</i> , 2013, 77, 249-274.	0.7	139
409	Widening indications for CRT implants: not necessarily "the more the merrier". <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 364-365.	0.2	0
410	Development and feasibility testing of decision support for patients who are candidates for a prophylactic implantable defibrillator: a study protocol for a pilot randomized controlled trial. <i>Trials</i> , 2013, 14, 346.	0.7	14



#	ARTICLE	IF	CITATIONS
411	Ultrafiltration: contemporary management of fluid overload. <i>British Journal of Hospital Medicine</i> (London, England: 2005), 2013, 74, C134-C138.	0.2	1
412	Standardization of QRS Duration Measurement and LBBB Criteria in CRT Trials and Clinical Practice. <i>Current Cardiology Reviews</i> , 2013, 9, 20-23.	0.6	8
413	The High-Risk Patient With Heart Failure With Reduced Ejection Fraction: Treatment Options and Challenges. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 509-518.	2.3	2
414	Cardiology Symposium. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2013, 43, 159-160.	0.2	0
415	Heart Failure Society of South Africa (HeFSSA) perspective on the European Society of Cardiology (ESC) 2012 chronic heart failure guideline. <i>South African Medical Journal</i> , 2013, 103, 660.	0.2	11
417	Facts and Principles Learned at the 39th Annual Williamsburg Conference on Heart Disease. <i>Baylor University Medical Center Proceedings</i> , 2013, 26, 124-136.	0.2	2
418	Predictors of Cardiac Resynchronization Therapy Response: The Pivotal Role of Electrocardiogram. <i>Scientific World Journal, The</i> , 2013, 2013, 1-6.	0.8	5
419	Management of heart failure. <i>Medical Journal of Australia</i> , 2013, 199, 334-339.	0.8	34
420	Cardiac resynchronization therapy with or without defibrillator: experience from a high-volume Belgian implantation centre. <i>Acta Cardiologica</i> , 2013, 68, 37-45.	0.3	5
421	Current Status of Heart Transplantation. , 2014, , 403-423.		0
422	Device Therapies: New Indications and Future Directions. <i>Current Cardiology Reviews</i> , 2014, 11, 33-41.	0.6	9
423	Individualized cardiac resynchronization therapy: current status. <i>Research Reports in Clinical Cardiology</i> , 2014, , 305.	0.2	0
424	Predictors for Cardiac Resynchronization Therapy Response. <i>International Heart Journal</i> , 2014, 55, 256-263.	0.5	10
426	Cardiac resynchronization therapy: the state of the art. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 573-587.	0.6	10
427	Regional variations in baseline characteristics of cardiac rhythm device recipients: The PANORAMA observational cohort study. <i>International Journal of Cardiology Heart &amp; Vessels</i> , 2014, 4, 90-96.	0.5	6
428	Pacing site in pacemaker dependency: is right ventricular septal lead position the answer?. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1407-1417.	0.6	4
429	Cardiac Resynchronization Therapy in Women. <i>JAMA Internal Medicine</i> , 2014, 174, 1340.	2.6	168
430	Superresponders to cardiac resynchronization therapy remain at risk for ventricular arrhythmias and benefit from defibrillator treatment. <i>European Journal of Heart Failure</i> , 2014, 16, 1104-1111.	2.9	34

#	ARTICLE	IF	CITATIONS
431	Almanac 2013: heart failure. <i>Anatolian Journal of Cardiology</i> , 2014, 14, 313-318.	0.4	0
432	Complex cardiac pacing in the setting of a district general hospital: procedural success and complications. <i>Heart Asia</i> , 2014, 6, 94-99.	1.1	1
433	Development of a Technique for Left Ventricular Endocardial Pacing via Puncture of the Interventricular Septum. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 17-22.	2.1	57
434	Is Cardiac Resynchronization Therapy for Right Ventricular Failure in Pulmonary Arterial Hypertension of Benefit?. <i>Pulmonary Circulation</i> , 2014, 4, 552-559.	0.8	12
435	CardioPulse Articles. <i>European Heart Journal</i> , 2014, 35, 943-950.	1.0	1
436	Left ventricular lead stabilization to retain cardiac resynchronization therapy at long term: when is it advisable?. <i>Europace</i> , 2014, 16, 533-540.	0.7	28
437	Awareness of indications for device therapy among a broad range of physicians: a survey study. <i>Europace</i> , 2014, 16, 1580-1586.	0.7	17
438	New-onset left bundle branch block independently predicts long-term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry. <i>Europace</i> , 2014, 16, 1450-1459.	0.7	48
439	Idiopathic ventricular fibrillation triggered by two distinct foci. <i>Europace</i> , 2014, 16, 1459-1459.	0.7	3
440	Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 926-934.	1.6	20
441	Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT (Multicenter Automatic Defibrillator) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 793-799.	0.7	39
442	The proarrhythmic effect of cardiac resynchronization therapy: An issue that should be borne in mind. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2014, 33, 309.e1-309.e7.	0.2	3
443	Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy. <i>Biomarkers in Medicine</i> , 2014, 8, 797-806.	0.6	1
445	Temporal Trends in Quality of Care Among Recipients of Implantable Cardioverter-Defibrillators. <i>Circulation</i> , 2014, 129, 580-586.	1.6	18
446	QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study. <i>Europace</i> , 2014, 16, 803-811.	0.7	19
447	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 2780-2787.	0.8	163
448	Present Guidelines for Device Implantation. <i>Circulation</i> , 2014, 129, 383-394.	1.6	28
449	The Characteristics and Outcome of Infective Endocarditis Involving Implantable Cardiac Devices. <i>Current Infectious Disease Reports</i> , 2014, 16, 446.	1.3	5



#	ARTICLE	IF	CITATIONS
450	A Pilot Study Evaluating Daily Physical Activity Before and After Cardiac Resynchronization Therapy. <i>Biological Research for Nursing</i> , 2014, 16, 31-37.	1.0	1
451	Cardiac Resynchronization Therapy in Adult Patients with Repaired Tetralogy of Fallot and Left Ventricular Systolic Dysfunction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 321-328.	0.5	23
452	QRS frequency characteristics help predict response to cardiac resynchronization in left bundle branch block less than 150 milliseconds. <i>Heart Rhythm</i> , 2014, 11, 2183-2189.	0.3	5
453	Frequency and Sequelae of Retained Implanted Cardiac Device Material Post Heart Transplantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 242-248.	0.5	24
454	Cardiac Resynchronization Therapy: Extending Current Responses to Phrenic Nerve Stimulation. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 491-493.	0.8	0
455	Renal Dysfunction and Clinical Outcomes of Patients Undergoing ICD and CRTD Implantation: Data from the Israeli ICD Registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 990-997.	0.8	13
456	Examining Achilles™ Heel. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1249-1250.	2.3	2
457	Survival in Octogenarians Undergoing Cardiac Resynchronization Therapy Compared to the General Population. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 740-744.	0.5	13
458	Strategies to improve cardiac resynchronization therapy. <i>Nature Reviews Cardiology</i> , 2014, 11, 481-493.	6.1	75
459	Development and optimization of SPECT gated blood pool cluster analysis for the prediction of CRT outcome. <i>Medical Physics</i> , 2014, 41, 072506.	1.6	5
460	Is Defibrillation Testing Necessary for Implantable Transvenous Defibrillators?. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 347-351.	2.1	13
462	Advanced left-ventricular lead placement techniques for cardiac resynchronization therapy. <i>Current Opinion in Cardiology</i> , 2014, 29, 53-58.	0.8	10
463	Superresponse to Cardiac Resynchronization Therapy. <i>Circulation</i> , 2014, 130, 87-90.	1.6	50
464	Cardiac resynchronization therapy. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 269-272.	0.6	6
465	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Circulation</i> , 2014, 130, 94-125.	1.6	102
466	Predictors of Spontaneous Reverse Remodeling in Mild Heart Failure Patients With Left Ventricular Dysfunction. <i>Circulation: Heart Failure</i> , 2014, 7, 565-572.	1.6	24
467	Left Ventricular Hypertrophy: A Major Factor of Risk in Black Hypertensive Patients. <i>American Journal of Hypertension</i> , 2014, 27, 1-2.	1.0	6
468	REVERSE 5-year follow up: CRT impact persists. <i>Global Cardiology Science &amp; Practice</i> , 2014, 2014, 39.	0.3	0

#	ARTICLE	IF	CITATIONS
469	Clinical Effectiveness of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Men and Women With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 146-153.	1.6	39
470	Ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction. <i>Current Opinion in Cardiology</i> , 2014, 29, 152-159.	0.8	6
471	Cardiac Implantable Electronic Device Removal in Patients with Left Ventricular Assist Device Associated Infections. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 1199-1205.	0.8	12
472	Cardiac Resynchronization Therapy in Patients with Renal Dysfunction: Keep Calm and Carry On. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 1196-1198.	0.8	1
473	Effects of smoking in patients treated with cardiac resynchronization therapy. <i>Internal and Emergency Medicine</i> , 2014, 9, 311-318.	1.0	0
474	Indications for Cardiac Resynchronization Therapy. <i>Cardiology Clinics</i> , 2014, 32, 293-298.	0.9	2
475	Chronic right ventricular apical pacing: Adverse effects and current therapeutic strategies to minimize them. <i>International Journal of Cardiology</i> , 2014, 173, 351-360.	0.8	43
476	A Metric for Evaluating the Cardiac Response to Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2014, 113, 1371-1377.	0.7	11
477	The Canadian Experience with Device and Lead Advisories. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 327-334.	0.7	0
478	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Heart Rhythm</i> , 2014, 11, 1270-1303.	0.3	16
479	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. <i>Journal of the American College of Cardiology</i> , 2014, 63, 853-871.	1.2	102
480	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1143-1177.	1.2	118
481	Clinical Implications of Conduction Abnormalities and Arrhythmias After Transcatheter Aortic Valve Implantation. <i>Current Cardiology Reports</i> , 2014, 16, 429.	1.3	14
482	SPECT gated blood pool phase analysis of lateral wall motion for prediction of CRT response. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 559-569.	0.7	10
483	Periprocedural Management of Cardiac Resynchronization Therapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 298.	0.4	0
484	Single-center experience of a quadripolar pacing lead for cardiac resynchronization therapy. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 39, 161-165.	0.6	12
486	The Relationship Between Cardiac Resynchronization Therapy and Diastolic Function. <i>Current Heart Failure Reports</i> , 2014, 11, 64-69.	1.3	10
487	Which Patients with AV Block Should Receive CRT Pacing?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 291.	0.4	2

#	ARTICLE	IF	CITATIONS
488	The Effect of Intermittent Atrial Tachyarrhythmia on Heart Failure or Death in Cardiac Resynchronization Therapy With Defibrillator Versus Implantable Cardioverter-Defibrillator Patients. Journal of the American College of Cardiology, 2014, 63, 1190-1197.	1.2	28
491	Long-Term Functional and Clinical Follow-Up of Patients With Heart Failure With Recovered Left Ventricular Ejection Fraction After $\beta$ -Blocker Therapy. Circulation: Heart Failure, 2014, 7, 434-439.	1.6	78
492	The Role of Coronary Artery Disease in Heart Failure. Heart Failure Clinics, 2014, 10, 353-365.	1.0	96
493	Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure. New England Journal of Medicine, 2014, 370, 1694-1701.	13.9	283
494	Bradycardia and Pacemakers/CRT. , 2014, , 423-438.		0
495	Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: A multinational 10-year experience. American Heart Journal, 2014, 167, 203-209.e1.	1.2	22
496	Clinical Benefit of Cardiac Resynchronization Therapy With a Defibrillator in Patients With an Ejection Fraction $\geq$ 35% Estimated by Cardiac Magnetic Resonance. Revista Espanola De Cardiologia (English Ed), 2014, 67, 107-113.	0.4	3
497	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. Canadian Journal of Cardiology, 2014, 30, 249-263.	0.8	44
498	Potential of resveratrol in the treatment of heart failure. Life Sciences, 2014, 95, 63-71.	2.0	84
499	Tissue-Engineered Cardiovascular Products. , 2014, , 1745-1764.		0
500	Management of ACCF/AHA Stage C Heart Failure. Cardiology Clinics, 2014, 32, 73-93.	0.9	8
501	Ventricular Arrhythmias in Heart Failure. , 2014, , 903-912.		0
502	CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. Europace, 2014, 16, 71-80.	0.7	64
503	Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). European Journal of Heart Failure, 2014, 16, 817-825.	2.9	148
504	The Effect of Left Ventricular Electrical Delay on the Acute Hemodynamic Response with Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 624-630.	0.8	27
505	Mortality Reduction in Relation to Implantable Cardioverter Defibrillator Programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circulation: Arrhythmia and Electrophysiology, 2014, 7, 785-792.	2.1	101
506	More Favorable Response to Cardiac Resynchronization Therapy in Women Than in Men. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 807-815.	2.1	65
507	Patient-assessed short-term positive response to cardiac resynchronization therapy is an independent predictor of long-term mortality. Europace, 2014, 16, 1603-1609.	0.7	9

#	ARTICLE	IF	CITATIONS
508	Progressive ventricular dysfunction among nonresponders to cardiac resynchronization therapy: Baseline predictors and associated clinical outcomes. <i>Heart Rhythm</i> , 2014, 11, 1991-1998.	0.3	13
509	Long term impact of cardiac contractility modulation on QRS duration. <i>Journal of Electrocardiology</i> , 2014, 47, 936-940.	0.4	20
510	Comparative Effectiveness of Cardiac Resynchronization Therapy in Combination With Implantable Defibrillator in Patients With Heart Failure and Wide QRS Duration. <i>American Journal of Cardiology</i> , 2014, 114, 1537-1542.	0.7	1
511	On the Underutilization of Cardiac Resynchronization Therapy. <i>Journal of Cardiac Failure</i> , 2014, 20, 696-705.	0.7	17
512	Treatment for Pulmonary Arterial Hypertension—Associated Right Ventricular Dysfunction. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1101-1115.	1.5	30
513	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, e1-e63.	0.8	200
514	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.	1.0	61
515	Clinical Effectiveness of CRT and ICD Therapy in Heart Failure Patients by Racial/Ethnic Classification. <i>Journal of the American College of Cardiology</i> , 2014, 64, 797-807.	1.2	32
516	Teraputica de ressincronizao cardaca e efeito prarrtmico: um problema que deve ser lembrado. <i>Revista Portuguesa De Cardiologia</i> , 2014, 33, 309.e1-309.e7.	0.2	2
517	Effects of Cardiac Resynchronization Therapy on Muscle Sympathetic Nerve Activity. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 11-18.	0.5	22
518	Chronic heart failure: epidemiology, investigation and management. <i>Medicine</i> , 2014, 42, 562-567.	0.2	10
519	Devices for heart failure. <i>Medicine</i> , 2014, 42, 568-573.	0.2	0
520	Does Cardiac Resynchronization Therapy Benefit Patients With Right Bundle Branch Block. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 532-542.	2.1	48
521	Does Cardiac Resynchronization Therapy Benefit Patients With Right Bundle Branch Block. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 543-552.	2.1	8
522	Left Ventricular Dyssynchrony Assessment Using Myocardial Single-Photon Emission CT. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 314-319.	2.5	15
523	Atrial fibrillation and heart failure: intersecting populations, morbidities, and mortality. <i>Heart Failure Reviews</i> , 2014, 19, 285-293.	1.7	19
524	Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation. <i>Europace</i> , 2014, 16, 1205-1209.	0.7	29
525	Left Ventricular Lead Position and Outcomes in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). <i>Canadian Journal of Cardiology</i> , 2014, 30, 413-419.	0.8	16

#	ARTICLE	IF	CITATIONS
527	Impact of Cardiac Resynchronization Therapy on Hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial. <i>Circulation</i> , 2014, 129, 2021-2030.	1.6	10
528	20 Years of Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1047-1058.	1.2	137
529	Effects of AV Delay and VV Delay on Left Atrial Pressure and Waveform in Ambulant Heart Failure Patients: Insights into CRT Optimization. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 810-819.	0.5	6
530	Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT. <i>Journal of the American College of Cardiology</i> , 2014, 64, 887-894.	1.2	85
531	Contemporary Strategies in the Diagnosis and Management of Heart Failure. <i>Mayo Clinic Proceedings</i> , 2014, 89, 662-676.	1.4	24
532	Whom Should I Refer in 2014 for Cardiac Resynchronization?. <i>Canadian Journal of Cardiology</i> , 2014, 30, 675-678.	0.8	8
533	Comentarios a la guÃa de prÃctica clÃca de la ESC 2013 sobre estimulaciÃn cardiaca y terapia de resincronizaciÃn cardiaca. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 6-14.	0.6	7
534	Cardiac resynchronization therapy restored ventricular septal myocardial perfusion and enhanced ventricular remodeling in patients with nonischemic cardiomyopathy presenting with left bundle branch block. <i>Heart Rhythm</i> , 2014, 11, 836-841.	0.3	24
535	Left ventricular ejection fraction overcrossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: Single center observational experience. <i>International Journal of Cardiology</i> , 2014, 172, 64-71.	0.8	18
536	Cardiac Resynchronization Therapy in Patients With Intermittent Atrial Arrhythmias. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1198-1199.	1.2	1
537	Outcomes in pacemaker-dependent patients upgraded from conventional pacemakers to cardiac resynchronization therapy-defibrillators. <i>Heart Rhythm</i> , 2014, 11, 1008-1014.	0.3	14
538	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease. <i>Heart Rhythm</i> , 2014, 11, e102-e165.	0.3	585
539	Troubleshooting the Malfunctioning CRT-D Device. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 217-226.	0.7	0
540	2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 58.	0.4	54
541	GuÃa de prÃctica clÃnica de la ESC 2013 sobre estimulaciÃn cardiaca y terapia de resincronizaciÃn cardiaca. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 58.e1-58.e60.	0.6	4
542	Newer Indications for ICD and CRT. <i>Cardiology Clinics</i> , 2014, 32, 181-190.	0.9	7
543	Novel active fixation mechanism permits precise placement of a left ventricular lead: Early results from a multicenter clinical study. <i>Heart Rhythm</i> , 2014, 11, 1150-1155.	0.3	28
544	Comments on the 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 6-14.	0.4	5

#	ARTICLE	IF	CITATIONS
545	Pre-Capillary Pulmonary Hypertension and Right Ventricular Dilation Predict Clinical Outcome in Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2014, 2, 230-237.	1.9	20
546	PR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 645-651.	2.1	98
547	Ventricular Arrhythmias in Super-responders to Cardiac Resynchronization Therapy. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2014, 67, 883-889.	0.4	8
548	Arritmias ventriculares en superrespondedores a la terapia de resincronizaci3n cardiaca. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 883-889.	0.6	22
549	A novel algorithm to assess risk of heart failure exacerbation using ICD diagnostics: Validation from RAFT. <i>Heart Rhythm</i> , 2014, 11, 1626-1631.	0.3	22
550	The Effect of Weight Loss on Clinical Outcomes in Patients Implanted With a Cardiac Resynchronization Therapy Device—A MADIT-CRT Substudy. <i>Journal of Cardiac Failure</i> , 2014, 20, 183-189.	0.7	12
551	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: Executive Summary. <i>Heart Rhythm</i> , 2014, 11, e81-e101.	0.3	33
553	Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone. <i>Annals of Internal Medicine</i> , 2014, 160, 603.	2.0	27
554	Usefulness of Phase Analysis to Differentiate Ischemic and Non-Ischemic Etiologies of Left Ventricular Systolic Dysfunction in Patients With Heart Failure. <i>Circulation Journal</i> , 2014, 78, 141-150.	0.7	18
555	Relationship between pre-implant ejection fraction and outcome after cardiac resynchronization therapy in symptomatic patients. <i>Acta Cardiologica</i> , 2014, 69, 424-432.	0.3	2
556	<i>Esc. Acta Cardiologica</i> , 2014, 69, 341-347.	0.3	0
557	Implementation of transmural disease management in patients admitted with advanced heart failure. <i>Acta Cardiologica</i> , 2014, 69, 145-154.	0.3	5
558	Efficacy of Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Compared With Combined Therapy in Survival of Patients With Heart Failure. <i>Medicine (United States)</i> , 2015, 94, e418.	0.4	3
559	Removal of the broken part of implantable cardioverter-defibrillator's electrode causing pulmonary embolism via femoral vein. <i>Indian Heart Journal</i> , 2015, 67, S88.e1-S88.e4.	0.2	0
560	Evaluation of Synergistic Effects of Resynchronization Therapy and a ð-blocker Up-titration Strategy Based on a Predefined Patient Management Program: The <sc>RESTORE</sc> Study. <i>Clinical Cardiology</i> , 2015, 38, 2-7.	0.7	7
561	Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: the <sc>VALIDâ€CRT</sc> risk score. <i>European Journal of Heart Failure</i> , 2015, 17, 717-724.	2.9	41
562	Early intervention and long-term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms. <i>European Journal of Heart Failure</i> , 2015, 17, 964-970.	2.9	11
563	Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASISâ€HF). <i>European Journal of Heart Failure</i> , 2015, 17, 707-716.	2.9	16



#	ARTICLE	IF	CITATIONS
564	Predicting outcomes following CRT: the quest continues. <i>European Journal of Heart Failure</i> , 2015, 17, 645-646.	2.9	2
565	Reduced risk of life-threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 971-978.	2.9	23
566	Cardiac resynchronization revisited: what is the next step?. <i>European Journal of Heart Failure</i> , 2015, 17, 881-883.	2.9	0
567	Treatment of Heart Failure in Real-World Clinical Practice: Findings From the <sc>REFLECT</sc> Registry in Patients With <sc>NYHA</sc> Class <sc>II</sc> Symptoms and a Reduced Ejection Fraction. <i>Clinical Cardiology</i> , 2015, 38, 200-207.	0.7	16
568	Complete Left Bundle Branch Block and Smaller Left Atrium Are Predictors of Response to Cardiac Resynchronization Therapy in Advanced Heart Failure. <i>Circulation Journal</i> , 2015, 79, 2414-2421.	0.7	7
569	Current Challenges in the Management of Heart Failure. <i>Circulation Journal</i> , 2015, 79, 948-953.	0.7	25
570	Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. <i>Annals of Internal Medicine</i> , 2015, 163, 417-426.	2.0	23
571	If Some Primary Prevention Implantable Cardioverter-Defibrillator Implants Are Futile, Can We Identify Them A Priori?. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 38-40.	1.3	1
572	Cardiac Resynchronization Therapy in 2015: Lessons Learned. <i>Cardiovascular Innovations and Applications</i> , 2015, 1, .	0.1	0
573	Long-Term Results of Cardiac Resynchronization Therapy: A Comparison between CRT-Pacemakers versus Primary Prophylactic CRT-Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 758-767.	0.5	17
574	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>European Journal of Heart Failure</i> , 2015, 17, 848-874.	2.9	32
575	Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 862-871.	0.8	46
576	Renal Response in Patients with Chronic Kidney Disease Predicts Outcome Following Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1192-1200.	0.5	13
577	Acute Hemodynamic Response to Cardiac Resynchronization in Dilated Cardiomyopathy: Effect on Late Mitral Regurgitation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1287-1296.	0.5	14
578	Frequent Premature Ventricular Contractions. <i>Cardiology in Review</i> , 2015, 23, 168-172.	0.6	12
579	Cardiac Resynchronization Therapy and QRS Duration: Systematic Review, Meta-analysis, and Meta-regression. <i>Journal of Korean Medical Science</i> , 2015, 30, 24.	1.1	11
580	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. <i>Italian Journal of Medicine</i> , 2015, 3, 309.	0.2	1
581	The FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) position paper on cardiovascular prevention in the higher risk complex patients. <i>Italian Journal of Medicine</i> , 2015, 9, 387.	0.2	1

#	ARTICLE	IF	CITATIONS
583	Impact of haematoma after pacemaker and CRT device implantation on hospitalization costs, length of stay, and mortality: a population-based study. <i>Europace</i> , 2015, 17, 1548-1554.	0.7	37
584	Pathophysiological links, echocardiographic characteristics, and clinical implications of QRS morphology in patients with dilated cardiomyopathy. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015, 9, 325-329.	1.0	4
585	Cardiac Resynchronization Therapy in "The Autumn of Life". <i>JACC: Heart Failure</i> , 2015, 3, 505-507.	1.9	1
586	Sex Differences in Device Therapy for Heart Failure: Utilization, Outcomes, and Adverse Events. <i>Journal of Women's Health</i> , 2015, 24, 261-271.	1.5	25
587	Global and Regional Functional Assessment of Ischemic Heart Disease with Cardiac MR Imaging. <i>Radiologic Clinics of North America</i> , 2015, 53, 369-395.	0.9	16
588	Clinical Management and Prevention of Sudden Cardiac Death. <i>Circulation Research</i> , 2015, 116, 2020-2040.	2.0	60
589	Assessing mitral regurgitation in the prediction of clinical outcome after cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2015, 12, 1201-1208.	0.3	26
590	Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial. <i>Heart Rhythm</i> , 2015, 12, 2010-2017.	0.3	25
591	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2618-2629.	1.2	26
592	Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. <i>Heart</i> , 2015, 101, 1800-1806.	1.2	112
593	Will the Real Left Bundle Branch Block Please Stand Up? <i>Journal of the American College of Cardiology</i> , 2015, 66, 642-644.	1.2	0
594	Current Technology to Maximize Cardiac Resynchronization Therapy Benefit for Patients With Symptomatic Heart Failure. <i>AACN Advanced Critical Care</i> , 2015, 26, 329-340.	0.6	3
596	Cardiac Resynchronization Therapy. , 2015, , 577-597.		0
597	Multipoint left ventricular pacing provides additional echocardiographic benefit to responders and non-responders to conventional cardiac resynchronization therapy. <i>European Heart Journal Supplements</i> , 2015, 17, A12-A17.	0.0	6
598	Detailed analysis of ventricular activation sequences during right ventricular apical pacing and left bundle branch block and the potential implications for cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2015, 12, 137-143.	0.3	36
599	European Cardiac Resynchronization Therapy Survey II: rationale and design. <i>Europace</i> , 2015, 17, 137-141.	0.7	22
600	Profile of St. Jude Medical's Allure Quadra quadripolar pacemaker system for cardiac resynchronization therapy. <i>Expert Review of Medical Devices</i> , 2015, 12, 41-48.	1.4	2
601	Use of Biomarkers for the Prediction of Treatment Response: Immunoabsorption in Dilated Cardiomyopathy as a Clinical Example. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 81-92.	0.6	0



#	ARTICLE	IF	CITATIONS
602	The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: Results of the REVERSE study. <i>Heart Rhythm</i> , 2015, 12, 524-530.	0.3	85
603	Epicardial leads in adult cardiac resynchronization therapy recipients: A study on lead performance, durability, and safety. <i>Heart Rhythm</i> , 2015, 12, 533-539.	0.3	20
604	Secondary Prevention After Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2015, 131, 927-964.	1.6	313
605	Analysis of ventricular function by CT. <i>Journal of Cardiovascular Computed Tomography</i> , 2015, 9, 1-12.	0.7	53
606	Singular Value Decomposition Applied to Cardiac Strain from MR Imaging for Selection of Optimal Cardiac Resynchronization Therapy Candidates. <i>Radiology</i> , 2015, 275, 413-420.	3.6	24
607	Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. <i>Heart</i> , 2015, 101, 1456-1462.	1.2	61
609	Safety and efficacy of external electrical cardioversion in patients with left ventricular leads. <i>Clinical Research in Cardiology</i> , 2015, 104, 439-445.	1.5	5
610	The mismatch between patient life expectancy and the service life of implantable devices in current cardioverter-defibrillator therapy: a call for larger device batteries. <i>Clinical Research in Cardiology</i> , 2015, 104, 456-460.	1.5	12
611	Comparison of pharmacological treatment alone versus treatment combined with cardiac resynchronization therapy in patients over 75 years. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 43, 13-20.	0.6	1
612	Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction. <i>Circulation: Heart Failure</i> , 2015, 8, 725-732.	1.6	18
613	Review of Eligibility for Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2015, 116, 318-324.	0.7	2
614	Prognostic implication of baseline PR interval in cardiac resynchronization therapy recipients. <i>Heart Rhythm</i> , 2015, 12, 2256-2262.	0.3	28
615	Clinical Practice Guideline (CPG). Recommendations on strategy for reducing risk of heart failure patients requiring noncardiac surgery. <i>Revista Española De Anestesiología Y Reanimación (English)</i> Tj ETQq0 0 OrgBT /Overlock 10 Tt		
616	CASE 10 "2015. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 1365-1375.	0.6	1
617	A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms. <i>Heart Failure Reviews</i> , 2015, 20, 545-552.	1.7	10
618	Review of heart failure treatment in type 2 diabetes patients: It's at least as effective as in non-diabetic patients!. <i>Diabetes and Metabolism</i> , 2015, 41, 446-455.	1.4	10
619	Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT. <i>Europace</i> , 2015, 17, 1816-1822.	0.7	11
620	Cardiac resynchronization therapy in patients with postero-lateral scar by cardiac magnetic resonance: A systematic review and meta-analysis. <i>Journal of Electrocardiology</i> , 2015, 48, 783-790.	0.4	21

#	ARTICLE	IF	CITATIONS
621	Do cardiologists follow the European guidelines for cardiac pacing and resynchronization therapy? Results of the European Heart Rhythm Association survey. <i>Europace</i> , 2015, 17, 148-151.	0.7	10
622	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2015, 3, 603-614.	1.9	36
623	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2015, 17, 135-143.	2.9	21
624	Right ventricular septal pacing in patients with right bundle branch block. <i>Journal of Electrocardiology</i> , 2015, 48, 626-629.	0.4	8
625	Preventing cardiac implantable electronic device infections. <i>Heart Rhythm</i> , 2015, 12, 2344-2356.	0.3	30
627	Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT?: Figure 1. <i>European Heart Journal</i> , 2015, 36, 1948-1951.	1.0	30
628	Chronic Heart failure – Therapeutic Approaches.. <i>Cardiologia Croatica</i> , 2015, 10, 46-50.	0.0	0
629	Narrow QRS systolic heart failure: is there a target for cardiac resynchronization?. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 783-797.	0.6	5
630	Opportunity to Increase Life Span in Narrow QRS Cardiac Resynchronization Therapy Recipients by Deactivating Ventricular Pacing. <i>JACC: Heart Failure</i> , 2015, 3, 327-336.	1.9	37
631	Cardiac Resynchronisation Therapy in Patients with Atrioventricular Nodal Disease and Reduced Ejection Fraction - Can We Afford it?. <i>Heart Lung and Circulation</i> , 2015, 24, 354-358.	0.2	2
632	The implantable cardioverter-defibrillator: An update. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 606-611.	2.3	19
634	Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2015, 11, 287-303.	1.0	26
635	Temporal Influence of Heart Failure Hospitalizations Prior to Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator on Subsequent Outcome in Mild Heart Failure Patients (from MADIT-CRT). <i>American Journal of Cardiology</i> , 2015, 115, 1423-1427.	0.7	5
636	Nonspecific intraventricular conduction delay: Definitions, prognosis, and implications for cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2015, 12, 1071-1079.	0.3	58
637	Cardiac resynchronisation therapy in patients with chronic heart failure. <i>Heart</i> , 2015, 101, 1008-1014.	1.2	12
638	Cardiac Resynchronization Therapy in Women Versus Men. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S4-11.	0.9	59
639	Seven years of use of implantable cardioverter-defibrillator therapies: a nationwide population-based assessment of their effectiveness in real clinical settings. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 22.	0.7	5
640	Incidence, Predictors, and Procedural Results of Upgrade to Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 152-158.	2.1	29

#	ARTICLE	IF	CITATIONS
641	Increase in paced heart rate reduces muscle sympathetic nerve activity in heart failure patients treated with cardiac resynchronization therapy. <i>Europace</i> , 2015, 17, 439-446.	0.7	5
642	Incidence, definition, diagnosis, and management of the cardiac resynchronization therapy nonresponder. <i>Current Opinion in Cardiology</i> , 2015, 30, 40-49.	0.8	34
643	Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2015, 31, 792-799.	0.8	25
644	Improving cardiac resynchronization therapy response with multipoint left ventricular pacing: Twelve-month follow-up study. <i>Heart Rhythm</i> , 2015, 12, 1250-1258.	0.3	98
645	Current Attitudes on Cardiac Devices in Heart Failure: A Review. <i>Clinical Therapeutics</i> , 2015, 37, 2206-2214.	1.1	9
646	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Europace</i> , 2015, 17, euv319.	0.7	635
647	Implantable Cardioverter-Defibrillator Use in Older Adults. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 437-446.	0.9	23
648	Electrocardiographic correlates of mechanical dyssynchrony in recipients of cardiac resynchronization therapy devices. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 617-625.	0.7	7
649	Left Ventricular Lead Electrical Delay Is a Predictor of Mortality in Patients With Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1113-1121.	2.1	43
650	Gaps and Resemblances in Current Heart Failure Guidelines. <i>Heart Failure Clinics</i> , 2015, 11, 529-541.	1.0	1
651	Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	28
652	Cardiac Resynchronization Therapy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 673-693.	0.7	4
653	Multipoint Left Ventricular Pacing in a Single Coronary Sinus Branch Improves Mid-Term Echocardiographic and Clinical Response to Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 58-63.	0.8	50
654	Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. <i>Heart Rhythm</i> , 2015, 12, 2402-2410.	0.3	39
655	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2015, 17, 1197-1214.	0.7	160
656	Long-term outcome with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block from US and Europe MADIT-CRT. <i>Heart Failure Reviews</i> , 2015, 20, 535-543.	1.7	4
657	Biventricular Pacemaker/Defibrillators Versus Biventricular Pacemakers in Patients with Non-ischemic Cardiomyopathy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 455-459.	0.7	2
658	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>European Heart Journal</i> , 2015, 36, 2793-2867.	1.0	3,187

#	ARTICLE	IF	CITATIONS
659	State of the art of leadless pacing. <i>Europace</i> , 2015, 17, 1508-1513.	0.7	73
660	Effect of Cardiac Resynchronization Therapy in Patients With Insulin-Treated Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2015, 116, 393-399.	0.7	8
661	Hospital-based and telemonitoring guided home-based training programs: Effects on exercise tolerance and quality of life in patients with heart failure (NYHA class III) and cardiac resynchronization therapy. A randomized, prospective observation.. <i>International Journal of Cardiology</i> , 2015, 199, 442-447.	0.8	58
662	Cardiac Resynchronization Therapy for Mild Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 701-702.	1.9	0
663	Generator Exchange in a Primary Prevention Cardiac Resynchronization Responder. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 487-496.	0.7	0
664	Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2015, 3, 691-700.	1.9	10
665	Coronary Sinus Lead Positioning. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 635-647.	0.7	1
666	Why We Have to Use Cardiac Resynchronization Therapy "Pacemaker More. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 709-720.	0.7	5
667	Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 695-707.	0.7	1
668	Cardiac Resynchronization Therapy in Women. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 721-734.	0.7	10
669	The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 765-779.	0.7	3
670	Cardiac Resynchronization Therapy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 789-796.	0.7	2
671	Clinical Practice Guideline (CPG). Recommendations on strategy for reducing risk of heart failure patients requiring noncardiac surgery. <i>Revista Española De Anestesiología Y Reanimación</i> , 2015, 62, 359-419.	0.1	7
672	Understanding Heart Failure. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 557-575.	0.7	20
673	Relation of QRS Duration to Response to Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 214-219.	0.7	25
674	Long-Term Outcomes in Patients With Ambulatory New York Heart Association Class III and IV Heart Failure Undergoing Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 82-85.	0.7	15
675	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
676	Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. <i>Europace</i> , 2015, 17, 424-431.	0.7	55

#	ARTICLE	IF	CITATIONS
677	Ventricular lead redundancy to prevent cardiovascular events and sudden death from lead fracture in pacemaker-dependent children. <i>Heart Rhythm</i> , 2015, 12, 111-116.	0.3	10
678	The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. <i>European Heart Journal</i> , 2015, 36, 440-448.	1.0	68
679	Multiple BiV Stimulation Combinations by using Two RV Leads Improve Potential for Response to CRT: Results of the TriV HF ICD Study. <i>Archives of Medicine</i> , 2016, 8, .	0.2	0
680	Echocardiography and Other Noninvasive Imaging Techniques in the Selection and Management of Patients with Cardiac Resynchronization Therapy. , 2016, , .		0
681	Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure management. <i>Singapore Medical Journal</i> , 2016, 57, 354-359.	0.3	9
682	Management of syncope: from evidence to clinical practice. <i>Italian Journal of Medicine</i> , 0, 10, .	0.2	1
683	Management del paziente con cefalea, vertigine e sincope: dalle evidenze alla pratica clinica. <i>Italian Journal of Medicine</i> , 2016, 4, 1.	0.2	0
684	Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. <i>Cardiovascular Diabetology</i> , 2016, 15, 93.	2.7	14
685	Management of Patients with Atrial Fibrillation: Focus on Treatment Options. <i>Journal of Atrial Fibrillation</i> , 2016, 9, 1450.	0.5	1
686	Cardiac Resynchronization Therapy in Women. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2016, 01, 005-010.	0.1	0
687	Treatment of Heart Failure With Reduced Ejection Fraction—Recent Developments. <i>American Journal of Therapeutics</i> , 2016, 23, e531-e549.	0.5	1
688	BLOCK HF. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 306-308.	0.6	5
689	Cardiac resynchronisation therapy in 2015: keeping up with the pace. <i>Internal Medicine Journal</i> , 2016, 46, 255-265.	0.5	1
690	Early right ventricular response to cardiac resynchronization therapy: impact on clinical outcomes. <i>European Journal of Heart Failure</i> , 2016, 18, 205-213.	2.9	13
691	Improving the Safety and Effectiveness of Medical Device Therapy in Women. <i>Journal of Women's Health</i> , 2016, 25, 428-430.	1.5	1
692	Women with nonischemic cardiomyopathy have a favorable prognosis and a better left ventricular remodeling than men after cardiac resynchronization therapy. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 291-298.	0.6	9
693	Vagus nerve stimulation: state of the art of stimulation and recording strategies to address autonomic function neuromodulation. <i>Journal of Neural Engineering</i> , 2016, 13, 041002.	1.8	74
694	Performance of Anatomically Designed Quadripolar Left Ventricular Leads: Results from the NAVIGATE X4 Clinical Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1199-1205.	0.8	20

#	ARTICLE	IF	CITATIONS
695	Cardiac resynchronisation therapy with an implantable cardioverter defibrillator appears to be cost-effective in patients with mild heart failure. Evidence-Based Medicine, 2016, 21, 88-88.	0.6	0
696	Left univentricular pacing for cardiac resynchronization therapy. Europace, 2017, 19, euw179.	0.7	13
699	Association of cardiac resynchronization therapy with the incidence of appropriate implantable cardiac defibrillator therapies in ischaemic and non-ischaemic cardiomyopathy. Europace, 2016, 19, euw303.	0.7	2
700	Quantitative Radionuclide Assessment of Cardiac Dyssynchrony: Breakthrough in Patient Selection for Cardiac Resynchronization Therapy for Refractory Heart Failure?. Journal of Nuclear Medicine, 2016, 57, 1840-1842.	2.8	3
701	Incidence, predictors and outcomes of hematoma after ICD implantation: An analysis of a nationwide database of 85,276 patients. Indian Pacing and Electrophysiology Journal, 2016, 16, 159-164.	0.3	17
703	Why QRS Duration Should Be Replaced by Better Measures of Electrical Activation to Improve Patient Selection for Cardiac Resynchronization Therapy. Journal of Cardiovascular Translational Research, 2016, 9, 257-265.	1.1	26
704	Multisite Pacing for Cardiac Resynchronization Therapy: Promise and Pitfalls. Current Cardiology Reports, 2016, 18, 64.	1.3	8
705	Toward Sex-Specific Guidelines for Cardiac Resynchronization Therapy?. Journal of Cardiovascular Translational Research, 2016, 9, 12-22.	1.1	13
706	Frequency and Outcomes of Postrandomization Atrial Tachyarrhythmias in the Resynchronization/Defibrillation in Ambulatory Heart Failure Trial. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	13
707	Non-invasive electromechanical activation imaging as a tool to study left ventricular dyssynchronous patients: Implication for CRT therapy. Journal of Electrocardiology, 2016, 49, 375-382.	0.4	11
708	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
709	2015 HRS/EHRA/APHS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Journal of Arrhythmia, 2016, 32, 1-28.	0.5	34
710	Tailor-made heart simulation predicts the effect of cardiac resynchronization therapy in a canine model of heart failure. Medical Image Analysis, 2016, 31, 46-62.	7.0	20
711	Effect of Cardiac Resynchronisation Therapy on Electrical Remodelling. Heart Lung and Circulation, 2016, 25, 471-475.	0.2	6
712	Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis. Heart Failure Reviews, 2016, 21, 447-453.	1.7	4
713	A Subclavian Arteriovenous Fistula Associated with Implantable Cardioverter-Defibrillator Implantation. Cardiac Electrophysiology Clinics, 2016, 8, 185-189.	0.7	1
714	Improvement in Clinical Outcomes With Biventricular Versus Right Ventricular Pacing. Journal of the American College of Cardiology, 2016, 67, 2148-2157.	1.2	83
715	Cardiac resynchronization therapy: results, challenges and perspectives for the future. Scandinavian Cardiovascular Journal, 2016, 50, 282-292.	0.4	6



#	ARTICLE	IF	CITATIONS
716	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	12
717	Ventricular Arrhythmia Burden in Patients With Heart Failure and Cardiac Resynchronization Devices: The Importance of Renal Function. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1328-1336.	0.8	4
718	Coupling of ventricular action potential duration and local strain patterns during reverse remodeling in responders and nonresponders to cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2016, 13, 1898-1904.	0.3	6
719	Letter from Liu and Yang Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial". <i>Circulation</i> , 2016, 134, e185-6.	1.6	0
720	Response by Di Biase et al to Letter Regarding Article, "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial". <i>Circulation</i> , 2016, 134, e189-90.	1.6	4
721	Women and heart disease, the underrecognized burden: sex differences, biases, and unmet clinical and research challenges. <i>Clinical Science</i> , 2016, 130, 551-563.	1.8	84
722	Status of cardiac resynchronization therapy in Catalonia, Spain: Results of the prospective multicentric study TRC-CAT. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 423-428.	0.1	1
723	Temporal trends in long-term mortality of patients with acute heart failure: Data from 1985 to 2008. <i>International Journal of Cardiology</i> , 2016, 224, 456-460.	0.8	10
724	Current treatment of heart failure with reduction of left ventricular ejection fraction. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1619-1631.	1.3	6
725	Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study. <i>International Journal of Cardiology</i> , 2016, 221, 951-956.	0.8	3
726	The arterial baroreflex effectiveness index in risk stratification of chronic heart failure patients who are candidates for cardiac resynchronization therapy. <i>Revista Portuguesa De Cardiologia (English)</i> 10 Tf 50	0.8	10
727	Non-responders to cardiac resynchronization therapy: Insights from multimodality imaging and electrocardiography. A brief review. <i>International Journal of Cardiology</i> , 2016, 225, 402-407.	0.8	28
728	Do we need to monitor the percentage of biventricular pacing day by day?. <i>International Journal of Cardiology</i> , 2016, 221, 81-89.	0.8	5
729	Current Treatment Strategies for Heart Failure: Role of Device Therapy and LV Reconstruction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 57.	0.4	10
730	Effect of Continued Cardiac Resynchronization Therapy on Ventricular Arrhythmias After Left Ventricular Assist Device Implantation. <i>American Journal of Cardiology</i> , 2016, 118, 556-559.	0.7	36
731	Magnitude of QRS duration reduction after biventricular pacing identifies responders to cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2016, 221, 450-455.	0.8	38
732	The importance of being "responder" in cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2016, 223, 838-841.	0.8	2
733	Cardiac resynchronization therapy improves functional status and cognition. <i>International Journal of Cardiology</i> , 2016, 219, 212-217.	0.8	16



#	ARTICLE	IF	CITATIONS
734	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
735	Autoantibodies against Î²1â€Adrenergic Receptors: Response to Cardiac Resynchronization Therapy and Renal Function. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 65-72.	0.5	3
736	Role of echocardiography before cardiac resynchronization therapy: new advances and current developments. Echocardiography, 2016, 33, 1745-1752.	0.3	23
737	Current Status of Left Ventricular Assist Device Therapy. Mayo Clinic Proceedings, 2016, 91, 927-940.	1.4	48
738	Does the presence of mitral regurgitation strengthen or weaken the indication for cardiac resynchronization therapy?. European Journal of Heart Failure, 2016, 18, 1069-1071.	2.9	0
739	How robust are clinical trials in heart failure?. European Heart Journal, 2017, 38, ehw427.	1.0	49
741	Cardiac Resynchronization Therapy in Older Patients: Age Is Just a Number, and Yet â€ . Journal of Cardiac Failure, 2016, 22, 978-980.	0.7	3
742	Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy. Circulation, 2016, 134, 1617-1628.	1.6	33
743	High Left Ventricular Lead Sensing Delay Predicts QRS Narrowing and Good Response to Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1317-1326.	0.5	3
744	Electromechanical cardioplasty using a wrapped elasto-conductive epicardial mesh. Science Translational Medicine, 2016, 8, 344ra86.	5.8	181
745	Defibrillators. Circulation, 2016, 134, 1390-1404.	1.6	32
746	Left Bundle Branch Block. JACC: Heart Failure, 2016, 4, 904-906.	1.9	3
747	Hemodynamic and neurochemical determinates of renal function in chronic heart failure. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R167-R175.	0.9	11
748	Predictors and Risk of Ventricular Tachyarrhythmias or Death in Black&White Cardiac Patients. JACC: Clinical Electrophysiology, 2016, 2, 448-455.	1.3	17
749	Sex and race differences in QRS duration. Europace, 2016, 18, euw065.	0.7	41
750	Effect of Gender on Outcomes After Cardiac Resynchronization Therapy in Patients With a Narrow QRS Complex. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	19
751	Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. Clinical Research in Cardiology, 2016, 105, 944-952.	1.5	41
752	Ventricular pacing â€“ Electromechanical consequences and valvular function. Indian Pacing and Electrophysiology Journal, 2016, 16, 19-30.	0.3	19

#	ARTICLE	IF	CITATIONS
753	Arrhythmia Management in the Elderly—Implanted Cardioverter Defibrillators and Prevention of Sudden Death. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1117-1123.	0.8	7
755	Cost analysis of telemedicine monitoring of patients with implantable cardioverter-defibrillators in the Czech Republic. <i>Cor Et Vasa</i> , 2016, 58, e293-e302.	0.1	4
756	Trends and determinant factors in the use of cardiac resynchronization therapy devices in Japan: Analysis of the Japan cardiac device treatment registry database. <i>Journal of Arrhythmia</i> , 2016, 32, 486-490.	0.5	21
757	The arterial baroreflex effectiveness index in risk stratification of chronic heart failure patients who are candidates for cardiac resynchronization therapy. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 343-350.	0.2	1
758	Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	13
759	Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD). <i>Heart Rhythm</i> , 2016, 13, 1987-1992.	0.3	38
760	The variability of automated QRS duration measurement. <i>Europace</i> , 2017, 19, euw015.	0.7	20
761	A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 936-947.	1.0	6
762	Relationship Between Reverse Remodeling and Cardiopulmonary Exercise Capacity in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy. <i>Journal of Cardiac Failure</i> , 2016, 22, 385-394.	0.7	10
763	Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. <i>International Journal of Cardiology</i> , 2016, 202, 349-355.	0.8	28
764	Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. <i>Europace</i> , 2016, 18, 1187-1193.	0.7	25
765	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. <i>Heart Rhythm</i> , 2016, 13, e50-e86.	0.3	197
766	Cardiac Resynchronization Therapy With a Quadripolar Electrode Lead Decreases Complications at 6 Months. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 212-220.	1.3	37
767	Chronic Heart Failure in Congenital Heart Disease. <i>Circulation</i> , 2016, 133, 770-801.	1.6	271
768	Differential Effects of Left Ventricular Pacing Sites on Regional Contraction Patterns and Global Performance. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 709-715.	0.6	0
769	Usefulness of cardiac resynchronisation therapy devices and implantable cardioverter defibrillators in the treatment of heart failure due to severe systolic dysfunction: systematic review of clinical trials and network meta-analysis. <i>Heart Asia</i> , 2016, 8, 8-15.	1.1	4
770	Heart failure — what the general physician needs to know. <i>Clinical Medicine</i> , 2016, 16, 25-33.	0.8	1
771	Are CRT upgrade procedures more complex and associated with more complications than de novo CRT implantations? A single centre experience. <i>Netherlands Heart Journal</i> , 2016, 24, 75-81.	0.3	15

#	ARTICLE	IF	CITATIONS
773	Predictors of response to cardiac resynchronization therapy in chronic heart failure patients. Egyptian Heart Journal, 2016, 68, 227-236.	0.4	6
774	Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure. Heart Failure Reviews, 2016, 21, 433-446.	1.7	9
775	Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease. Annals of Pharmacotherapy, 2016, 50, 475-485.	0.9	9
776	QRS Duration or QRS Morphology. Journal of the American College of Cardiology, 2016, 67, 1104-1117.	1.2	77
777	Heart Failure. Nursing Clinics of North America, 2016, 51, 13-27.	0.7	2
778	Cardiac Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003108.	2.1	47
779	Bipolar left ventricular pacing is associated with significant reduction in heart failure or death in CRT-D patients with LBBB. Heart Rhythm, 2016, 13, 1468-1474.	0.3	11
780	Left ventricular regional contraction abnormalities by echocardiographic speckle tracking in combined right bundle branch with left anterior fascicular block compared to left bundle branch block. Journal of Electrocardiology, 2016, 49, 353-361.	0.4	13
781	Right bundle branch block and heart failure: Can a bifocal right ventricular pacing be an alternative to biventricular pacing?. Cor Et Vasa, 2016, 58, e391-e395.	0.1	0
782	Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study. European Heart Journal, 2016, 37, 473-483.	1.0	57
783	Mechanical Dyssynchrony: A Risk Factor but not a Target. European Heart Journal, 2016, 37, 60-62.	1.0	5
784	Reduced long-term overall mortality in heart failure patients with prolonged QRS treated with CRT combined with ICD vs. heart failure patients with narrow QRS treated with ICD only. Europace, 2016, 18, 1374-1382.	0.7	10
785	Radionuclide Assessment of Left Ventricular Dyssynchrony. Cardiology Clinics, 2016, 34, 101-118.	0.9	9
786	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2016, 18, 159-183.	0.7	135
787	Comparative long-term outcomes after cardiac resynchronization therapy in right ventricular paced patients versus native wide left bundle branch block patients. Heart Rhythm, 2016, 13, 511-518.	0.3	29
788	Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management. Heart and Vessels, 2016, 31, 1109-1116.	0.5	10
789	Echocardiography and cardiac resynchronization therapy. Cor Et Vasa, 2016, 58, e340-e351.	0.1	6
790	Epicardial or transvenous leads: Controversial for the placement in implantation of cardiac resynchronization therapy. International Journal of Cardiology, 2016, 202, 834-835.	0.8	1

#	ARTICLE	IF	CITATIONS
791	Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. <i>European Heart Journal</i> , 2016, 37, 24-34.	1.0	512
792	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. <i>Journal of Cardiac Failure</i> , 2016, 22, 143-149.	0.7	9
793	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2016, 18, 12-36.	0.7	66
794	First clinical evaluation of an atrial haemodynamic sensor lead for automatic optimization of cardiac resynchronization therapy. <i>Europace</i> , 2016, 18, 755-761.	0.7	8
795	Lessons learned from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 137-146.	2.3	7
796	New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 366-376.	2.9	28
797	Physiology of Cardiac Pacing and Resynchronization. , 2017, , 213-248.		4
798	A new use for maximum deflection index: Detection of intraventricular dyssynchrony. <i>Journal of Electrocardiology</i> , 2017, 50, 301-306.	0.4	0
799	Advances and Future Directions in Cardiac Pacemakers. <i>Journal of the American College of Cardiology</i> , 2017, 69, 211-235.	1.2	69
800	New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 1-6.	0.7	2
801	Atrial Fibrillation and Ventricular Arrhythmias. <i>Circulation</i> , 2017, 135, 593-608.	1.6	90
802	Arrhythmia treatment "evidence catching up with technology. <i>Nature Reviews Cardiology</i> , 2017, 14, 75-76.	6.1	0
803	Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. <i>Europace</i> , 2017, 19, 1848-1854.	0.7	10
804	Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator. <i>JAMA Cardiology</i> , 2017, 2, 561.	3.0	16
806	Acute Effects of Multisite Biventricular Pacing on Dyssynchrony and Hemodynamics in Canines With Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 304-311.	0.7	4
807	Should women have different ECG criteria for CRT than men?. <i>Journal of Cardiology</i> , 2017, 70, 1-6.	0.8	6
808	Primary Prevention of Sudden Cardiac Death With Device Therapy in Urban and Rural Populations. <i>Canadian Journal of Cardiology</i> , 2017, 33, 437-442.	0.8	13
809	Trends and outcomes of cardiac resynchronization therapy upgrade procedures: A comparative analysis using a United States National Database 2003-2013. <i>Heart Rhythm</i> , 2017, 14, 1043-1050.	0.3	32

#	ARTICLE	IF	CITATIONS
810	Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?. <i>Heart Failure Reviews</i> , 2017, 22, 305-316.	1.7	2
811	QRS duration versus morphology and survival after cardiac resynchronization therapy. <i>ESC Heart Failure</i> , 2017, 4, 23-30.	1.4	14
812	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization. <i>JACC: Heart Failure</i> , 2017, 5, 169-178.	1.9	34
813	Impact of <sc>QRS</sc> complex duration and morphology on left ventricular reverse remodelling and left ventricular function improvement after cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 1145-1151.	2.9	20
814	Dilated cardiomyopathy. <i>Lancet, The</i> , 2017, 390, 400-414.	6.3	445
815	Very Wide QRS Complex (>180 ms) and CRT Efficacy. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2037-2038.	1.2	0
816	Implantable Cardioverter-Defibrillators With Versus Without Resynchronization Therapy in Patients With a QRS Duration >180 ms. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2026-2036.	1.2	13
817	Use of a pocket compression device for the prevention and treatment of pocket hematoma after pacemaker and defibrillator implantation (STOP-HEMATOMA-I). <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 49, 197-204.	0.6	15
818	Cardiac resynchronization therapy in ischemic and non-ischemic cardiomyopathy. <i>Journal of Arrhythmia</i> , 2017, 33, 410-416.	0.5	27
819	Effects of epicardial versus transvenous left ventricular lead placement on left ventricular function and cardiac perfusion in cardiac resynchronization therapy: A randomized clinical trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 917-923.	0.8	15
820	Multiple Comorbidities and Response to Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2369-2379.	1.2	37
821	Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. <i>JACC: Heart Failure</i> , 2017, 5, 388-392.	1.9	11
822	Coronary Sinus Lead Positioning. <i>Heart Failure Clinics</i> , 2017, 13, 79-91.	1.0	7
823	Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. <i>Heart Failure Clinics</i> , 2017, 13, 139-151.	1.0	0
824	The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2017, 13, 209-223.	1.0	11
825	Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2017, 13, 233-240.	1.0	14
826	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. <i>American Heart Journal</i> , 2017, 189, 48-58.	1.2	29
827	Letter by Barakat et al Regarding Article, "Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis". <i>Circulation</i> , 2017, 135, e1196-e1197.	1.6	0

#	ARTICLE	IF	CITATIONS
828	The Impact of the PR Interval in Patients Receiving Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 818-826.	1.3	5
829	Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. <i>Clinical Cardiology</i> , 2017, 40, 746-751.	0.7	13
830	Heart Failure Complicating Acute Myocardial Infarction. <i>Heart Failure Clinics</i> , 2017, 13, 513-525.	1.0	4
831	Update cardiac resynchronization therapy. <i>Journal of General and Family Medicine</i> , 2017, 18, 195-199.	0.3	1
832	The effects of gender on electrical therapies for the heart: procedural considerations, results and complications. <i>Europace</i> , 2017, 19, 1911-1921.	0.7	3
833	The effects of gender on electrical therapies for the heart: physiology, epidemiology, and access to therapies. <i>Europace</i> , 2017, 19, 1418-1426.	0.7	16
834	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults. <i>Heart Failure Clinics</i> , 2017, 13, 467-483.	1.0	3
835	Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. <i>Heart Rhythm</i> , 2017, 14, 858-865.	0.3	26
836	Electrical treatment of atrial arrhythmias in heart failure patients implanted with a dual defibrillator CRT device. Results from the TRADE-HF study. <i>International Journal of Cardiology</i> , 2017, 236, 181-186.	0.8	1
837	Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1669-1678.	1.2	56
839	Current status of mechanical circulatory support for treatment of advanced end-stage heart failure: successes, shortcomings and needs. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 377-387.	0.6	10
840	Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	31
841	Relation of QRS Duration to Response to Cardiac Resynchronization Therapy in Patients With Left Bundle Branch Block. <i>American Journal of Cardiology</i> , 2017, 119, 1803-1808.	0.7	10
842	Criteria for use of composite end points for competing risks—a systematic survey of the literature with recommendations. <i>Journal of Clinical Epidemiology</i> , 2017, 82, 4-11.	2.4	31
843	Cardiac Resynchronization Therapy in Women. <i>Heart Failure Clinics</i> , 2017, 13, 165-178.	1.0	9
844	Does Cardiac Resynchronization Therapy Benefit Patients with Non-Left Bundle Branch Block Prolonged QRS Patterns?. <i>Current Cardiology Reports</i> , 2017, 19, 125.	1.3	11
845	Predictors and outcomes of cardiac resynchronization therapy extended to the second generator. <i>Heart Rhythm</i> , 2017, 14, 1793-1800.	0.3	8
846	Device Management in Heart Failure. <i>Current Cardiology Reports</i> , 2017, 19, 114.	1.3	1

#	ARTICLE	IF	CITATIONS
847	Cardiac resynchronisation therapy: current indications, management and basic troubleshooting. <i>Heart</i> , 2017, 103, heartjnl-2016-310656.	1.2	8
848	Implantable and Wearable Defibrillator Therapy. <i>Cardiovascular Medicine</i> , 2017, , 131-142.	0.0	0
849	Right Ventricular Pacing Increases Risk of Appropriate Implantable Cardioverterâ€“Defibrillator Shocks Asymmetrically. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	9
850	Precision Medicine for Cardiac Resynchronization. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	14
851	Cardiac resynchronization therapy and its role in the management of heart failure. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2017, 78, 312-319.	0.2	3
852	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	0.8	503
853	Cardiac Resynchronization Therapy. <i>Cardiology in Review</i> , 2017, 25, 6-11.	0.6	7
855	Novel Pacing Strategies for Heart Failure Management. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 64.	0.4	1
856	Is an Admission for Decompensated Heart Failure Inevitable?. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 171-177.	1.6	9
857	Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricularâ€“only pacing. <i>European Journal of Heart Failure</i> , 2017, 19, 950-957.	2.9	33
858	Resposta universal Ã terapÃ“utica de ressincronizaÃ§Ã£o cardÃ“aca â€“ um desafio por resolver. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 427-430.	0.2	0
859	Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2017, 120, 262-266.	0.7	6
860	Impact of baseline renal function on allâ€“cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and metaâ€“analysis. <i>Journal of Arrhythmia</i> , 2017, 33, 417-423.	0.5	12
861	Universal response to cardiac resynchronization therapy: A challenge still to be overcome. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 427-430.	0.2	0
862	Bioelectrical signals improve cardiac function and modify gene expression of extracellular matrix components. <i>ESC Heart Failure</i> , 2017, 4, 291-300.	1.4	9
863	End of life decisions in heart failure. <i>Current Opinion in Cardiology</i> , 2017, 32, 224-228.	0.8	1
864	Updates in Cardiac Resynchronization Therapy for Chronic Heart Failure: Review of Multisite Pacing. <i>Current Heart Failure Reports</i> , 2017, 14, 376-383.	1.3	15
865	Cardiac Resynchronization Therapy in Heart Failure: Do Evidence-Based Guidelines Follow the Evidence?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	2



#	ARTICLE	IF	CITATIONS
866	Enhancing Response in the Cardiac Resynchronization Therapy Patient. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1203-1219.	1.3	18
867	Implantable Cardioverter-Defibrillator Implantation, Continuation, and Deactivation in Elderly Patients. <i>Current Geriatrics Reports</i> , 2017, 6, 279-289.	1.1	2
868	The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2017, 14, 1748-1755.	0.3	37
869	Cardiac Resynchronization Therapy in Older Adults with Heart Failure. <i>Heart Failure Clinics</i> , 2017, 13, 581-587.	1.0	7
870	Pilot study using 3D longitudinal strain computation in a multi-parametric approach for best selecting responders to cardiac resynchronization therapy. <i>Cardiovascular Ultrasound</i> , 2017, 15, 15.	0.5	7
871	Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2017, 7, e016352.	0.8	25
872	Effect of Significant Weight Change on Inappropriate Implantable Cardioverter-Defibrillator Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 9-16.	0.5	4
873	Device-related infective endocarditis in cardiac resynchronization therapy recipients – Single center registry with over 2500 person-years follow up. <i>International Journal of Cardiology</i> , 2017, 227, 18-24.	0.8	17
874	Interventional Techniques for Device Implantation. , 2017, , 841-901.		0
875	Cardiac resynchronization therapy in patients with mild heart failure is a reversal therapy. <i>Indian Heart Journal</i> , 2017, 69, 112-118.	0.2	1
876	Cardiac Pacing and Defibrillation Devices: Cost and Effectiveness. <i>Annual Review of Medicine</i> , 2017, 68, 1-13.	5.0	13
877	Percutaneous Treatment of Cardiovascular Diseases in Women. , 2017, , .		0
878	Right heart-pulmonary circulation unit and cardiac resynchronization therapy. <i>American Heart Journal</i> , 2017, 185, 1-16.	1.2	12
879	Understanding Heart Failure. <i>Heart Failure Clinics</i> , 2017, 13, 1-19.	1.0	45
880	Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2017, 13, 117-137.	1.0	12
881	Why We Have to Use Cardiac Resynchronization Therapy – Pacemaker More. <i>Heart Failure Clinics</i> , 2017, 13, 153-164.	1.0	6
883	What happens to non-responders in cardiac resynchronization therapy?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 885-892.	0.2	2
884	What happens to non-responders in cardiac resynchronization therapy?. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 885-892.	0.2	5

#	ARTICLE	IF	CITATIONS
885	Anesthetic Management of Laser Lead Extraction for Cardiovascular Implantable Electronic Devices. Seminars in Cardiothoracic and Vascular Anesthesia, 2017, 21, 302-311.	0.4	7
886	The effectiveness of CRT on improvement of survival of heart failure patients in real life clinical settings. Acta Cardiologica, 2017, 72, 180-187.	0.3	0
887	Sympathetic Blockade for Dysrhythmia Management in Heart Failure: Rationale and Therapeutic Progression to Intervention. , 0, , .		0
888	Cardiac Resynchronization Therapy. , 2017, , 490-522.		0
889	Current Therapeutic Options for Heart Failure in Elderly Patients. BioMed Research International, 2017, 2017, 1-11.	0.9	13
890	Mitochondrial Cardiomyopathy Presenting as Dilated Phase of Hypertrophic Cardiomyopathy Diagnosed with Histological and Genetic Analyses. Case Reports in Cardiology, 2017, 2017, 1-4.	0.1	3
891	Defibrillation Therapy. , 2017, , 464-481.		0
892	Cardiac Resynchronization Therapy Programming and Troubleshooting. , 2017, , 1090-1132.		2
893	Managing Advisories of Cardiac Implantable Electronic Devices. , 2017, , 1175-1190.		1
894	Cardiac Resynchronization Therapy: Who Benefits?. Annals of Global Health, 2018, 80, 61.	0.8	7
895	Cardiac Resynchronization Therapyâ€™Emerging Therapeutic Approaches. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 20.	0.4	4
896	A cohort study of cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy. Europace, 2018, 20, 1813-1818.	0.7	8
897	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patientsâ€™who is doing what to whom and how?. European Journal of Heart Failure, 2018, 20, 1039-1051.	2.9	107
898	Cardiac implantable electrical devices in women. Clinical Cardiology, 2018, 41, 232-238.	0.7	9
899	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434
900	Left ventricular lead implantation in cardiac resynchronization therapyÂˆ(CRT): A challenging procedure. Hellenic Journal of Cardiology, 2018, 59, 34-35.	0.4	2
901	Usefulness of Electrocardiographic Left Atrial Abnormality to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure and Left Bundle Branch Block (a) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 10 0.7	0.7	7
902	Longâ€™term outcomes of heart failure patients who received primary prevention implantable cardioverterâ€™defibrillator: An observational study. Journal of Arrhythmia, 2018, 34, 46-54.	0.5	8

#	ARTICLE	IF	CITATIONS
903	Cardiac resynchronization therapy: How did consensus guidelines from Europe and the United States evolve in the last 15 years?. <i>International Journal of Cardiology</i> , 2018, 261, 119-129.	0.8	18
904	Concise Review: Rational Use of Mesenchymal Stem Cells in the Treatment of Ischemic Heart Disease. <i>Stem Cells Translational Medicine</i> , 2018, 7, 543-550.	1.6	76
905	Differentiating Ventricular From Supraventricular Arrhythmias Using the Postpacing Interval After Failed Antitachycardia Pacing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005921.	2.1	2
906	Cardiac resynchronization therapy response in heart failure patients with different subtypes of true left bundle branch block. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 91-101.	0.6	10
907	Comparison of Long-Term Survival Benefits With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Versus Without Diabetes Mellitus (from the Multicenter Automatic Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 582 T Journal of Cardiology, 2018, 121, 1567-1574.	0.7	5
908	Prognostic value of nutrition status in the response of cardiac resynchronization therapy. <i>Indian Pacing and Electrophysiology Journal</i> , 2018, 18, 133-139.	0.3	4
909	Adherence to 2016 European Society of Cardiology guidelines predicts outcome in a large real-world population of heart failure patients requiring cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2018, 15, 1675-1682.	0.3	6
910	Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients >=75 Years Versus <75 Years Receiving Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2018, 121, 975-980.	0.7	1
911	When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?. <i>Cardiac Electrophysiology Clinics</i> , 2018, 10, 137-144.	0.7	11
912	Defining the pattern of initiation of monomorphic ventricular tachycardia using the beat-to-beat intervals recorded on implantable cardioverter defibrillators from the RAFT study: A computer-based algorithm. <i>Journal of Electrocardiology</i> , 2018, 51, 470-474.	0.4	4
913	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 342 Journal of Cardiology, 2018, 121, 1567-1574.	1.0	92
914	Lead-Related Complications. , 2018, , 166-170.		0
915	Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left-Bundle Branch Block. <i>Journal of the American College of Cardiology</i> , 2018, 71, 306-317.	1.2	71
916	Classic-Pattern Dyssynchrony in Adolescents and Adults With a Fontan Circulation. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 211-219.	1.2	30
917	Computational Modeling for Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2018, 11, 92-108.	1.1	48
918	Machine Learning Algorithm Predicts Cardiac Resynchronization Therapy Outcomes. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005499.	2.1	86
919	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 780-791.	2.9	81
920	Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. <i>American Heart Journal</i> , 2018, 197, 43-52.	1.2	27

#	ARTICLE	IF	CITATIONS
921	The prognostic value of high sensitive cardiac troponin I in patients receiving cardiac resynchronization therapy. <i>Acta Cardiologica</i> , 2018, 73, 141-146.	0.3	2
922	Ventricular Electrical Activation Delay and High-Frequency Electrocardiograms. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006396.	2.1	0
923	Right ventricular lead location, right-left ventricular lead interaction, and long-term outcomes in cardiac resynchronization therapy patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 185-194.	0.6	3
924	Cardiac resynchronization therapy in the Czech Republic - Data from the EHRA CRT Survey II multicenter registry. <i>Cor Et Vasa</i> , 2018, 60, e622-e630.	0.1	0
925	Indications for Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2018, 6, 308-316.	1.9	68
926	Pacemakers and Internal Cardioverter Defibrillators in Adult Congenital Heart Disease. , 2018, , 232-252.		0
927	Super-response to cardiac resynchronization therapy may predict late phrenic nerve stimulation. <i>Europace</i> , 2018, 20, 1498-1505.	0.7	2
928	Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology. <i>Heart Rhythm</i> , 2018, 15, 130-136.	0.3	15
929	Novel electrocardiographic dyssynchrony criteria improve patient selection for cardiac resynchronization therapy. <i>Europace</i> , 2018, 20, 97-103.	0.7	19
930	Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. <i>Europace</i> , 2018, 20, e1-e10.	0.7	131
931	Implant of permanent pacemaker during acute coronary syndrome: Mortality and associated factors in the ARIAM registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 224-229.	0.4	2
932	Contemporary Review of Left Bundle Branch Block in the Failing Heart – Pathogenesis, Prognosis, and Therapy. <i>Heart Lung and Circulation</i> , 2018, 27, 291-300.	0.2	10
933	Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy. <i>Europace</i> , 2018, 20, 1303-1311.	0.7	21
934	Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 769-777.	2.9	18
935	Early prediction of cardiac resynchronization therapy response by non-invasive electrocardiogram markers. <i>Medical and Biological Engineering and Computing</i> , 2018, 56, 611-621.	1.6	1
936	Assessment of dyssynchrony by gated myocardial perfusion imaging does not improve patient management. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 526-531.	1.4	4
937	Electrophysiology Catheter-Facilitated coronary sinus cannulation and implantation of cardiac resynchronization therapy systems. <i>Hellenic Journal of Cardiology</i> , 2018, 59, 26-33.	0.4	9
938	Cardiac Resynchronization Therapy. , 2018, , 475-488.		0

#	ARTICLE	IF	CITATIONS
939	Adverse Impact of Delayed Electrical Activation of the Heart and Benefits of Cardiac Resynchronization. , 2018, , 10-33.		0
940	Remote Monitoring of Cardiovascular Implantable Electronic Devices. , 2018, , 292-297.		0
941	Prevention of Sudden Cardiac Death. , 2018, , 321-336.		0
942	Left and Right Ventricular Remodeling. , 2018, , 171-185.		1
943	OBSOLETE: Cardiac Pacing and Monitoring: Past, Present, and Future. , 2018, , .		0
944	OBSOLETE: Left and Right Ventricular Remodeling. , 2018, , .		0
945	OBSOLETE: Remote Monitoring of Cardiac Implantable Electronic Devices. , 2018, , .		0
946	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nepriylsin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 1226.	3.0	38
947	Facility-Level Variation and Clinical Outcomes in Use of Cardiac Resynchronization Therapy With and Without an Implantable Cardioverter-Defibrillator. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004763.	0.9	8
948	Cardiac resynchronization therapy outcomes in patients under nonoptimal medical therapy. Journal of Arrhythmia, 2018, 34, 548-555.	0.5	3
949	Size Matters. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006767.	2.1	39
950	Echocardiography in Cardiac Resynchronization Therapy. , 2018, , 643-660.		0
951	Expanding the Clinical Classification of Heart Failure: Inclusion of Cardiac Function During Exercise. , 2018, , 65-86.		0
952	Effect of Cardiac Resynchronization Therapy on Exercise-Induced Pulmonary Hypertension and Right Ventricular-Arterial Coupling. Circulation: Cardiovascular Imaging, 2018, 11, e007813.	1.3	26
953	Inhibition of TRAF3 expression alleviates cardiac ischemia reperfusion (IR) injury: A mechanism involving in apoptosis, inflammation and oxidative stress. Biochemical and Biophysical Research Communications, 2018, 506, 298-305.	1.0	19
954	Whatâ€™s new in heart failure therapy 2018?â€™. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 921-930.	0.5	8
955	What is the most appropriate method for coronary sinus cannulation? The telescopic method or the electrophysiologic method?. PLoS ONE, 2018, 13, e0203534.	1.1	1
957	Gender Differences in Ischemic Cardiomyopathy. Current Atherosclerosis Reports, 2018, 20, 50.	2.0	21

#	ARTICLE	IF	CITATIONS
958	Permanent His Bundle Pacing for Cardiac Resynchronization Therapy in Patients With Heart Failure and Right Bundle Branch Block. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006613.	2.1	126
959	The stricter criteria for Class I CRT indication suggested by the 2016 ESC Guidelines reliably exclude patients with a worse prognosis in comparison with the 2013 ESC indication criteria. <i>International Journal of Cardiology</i> , 2018, 273, 162-167.	0.8	2
960	Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 1476-1480.	0.5	8
961	OBSOLETE: Adverse Impact of Delayed Electrical Activation of the Heart and Benefits of Cardiac Resynchronization. , 2018, , .		0
962	Upgrades from a previous device compared to <i>de novo</i> cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. <i>European Journal of Heart Failure</i> , 2018, 20, 1457-1468.	2.9	44
963	Eligibility for cardiac resynchronization therapy in patients hospitalized with heart failure. <i>ESC Heart Failure</i> , 2018, 5, 668-674.	1.4	8
964	Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2018, 20, 1565-1565ao.	0.7	186
965	Cardiac Resynchronization Therapy and Clinical Outcomes in Continuous Flow Left Ventricular Assist Device Recipients. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	30
966	Atrial electrogram quality in single-pass defibrillator leads with floating atrial bipole in patients with permanent atrial fibrillation and cardiac resynchronization therapy. <i>Indian Pacing and Electrophysiology Journal</i> , 2018, 18, 140-145.	0.3	1
967	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. <i>Heart Lung and Circulation</i> , 2018, 27, 1123-1208.	0.2	262
968	Cardiac Arrhythmia in Heart Failure. , 2018, , 394-410.		0
969	Baseline adverse electrical remodeling and the risk for ventricular arrhythmia in Cardiac Resynchronization Therapy Recipients (MADIT CRT). <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1017-1023.	0.8	0
970	The definition of left bundle branch block influences the response to cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2018, 269, 165-169.	0.8	43
971	Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1425-1435.	0.8	15
972	Natural progression of QRS duration in ICD-only patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 53, 47-51.	0.6	5
973	Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 343-352.	0.6	19
974	Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 70.	0.7	14
975	Device therapy in heart failure with reduced ejection fraction" cardiac resynchronization therapy and more. <i>Herz</i> , 2018, 43, 415-422.	0.4	10

#	ARTICLE	IF	CITATIONS
977	Cardiac Pacing and Monitoring: Past, Present, and Future. , 2018, , 463-467.		4
978	Non-response to Cardiac Resynchronization Therapy. <i>Current Heart Failure Reports</i> , 2018, 15, 315-321.	1.3	17
979	Predictors of long-term mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. <i>Clinical Cardiology</i> , 2018, 41, 1358-1366.	0.7	4
980	His Bundle Pacing: A New Frontier in the Treatment of Heart Failure. <i>Arrhythmia and Electrophysiology Review</i> , 2018, 7, 103.	1.3	50
981	FDA perspective on assessing the clinical benefit of cardiac resynchronization and implantable cardioverter-defibrillator devices. <i>Journal of Electrocardiology</i> , 2018, 51, S22-S24.	0.4	0
982	Importance of Right Ventricular and Left Ventricular Lead Placement in Cardiac Resynchronisation Therapy. , 2018, , 347-361.		0
983	Cardiac resynchronization therapy guided by cardiac magnetic resonance imaging: A prospective, single-centre randomized study (CMR-CRT). <i>International Journal of Cardiology</i> , 2018, 270, 325-330.	0.8	16
984	Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2019, 281, 179-185.	0.8	9
985	Heart Failure with Reduced Ejection Fraction. , 2019, , 383-395.		0
986	Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in Older Adults With Heart Failure. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2193-2199.	1.3	8
987	Cardiac resynchronization therapy in patients with heart failure and moderately reduced ejection fraction: Could it trigger a super-response?. <i>Indian Heart Journal</i> , 2019, 71, 229-234.	0.2	4
988	Incremental Value of Implantable Cardiac Device Diagnostic Variables Over Clinical Parameters to Predict Mortality in Patients With Mild to Moderate Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e010998.	1.6	6
989	The VALID-CRT risk score reliably predicts response and outcome of cardiac resynchronization therapy in a real-world population. <i>Clinical Cardiology</i> , 2019, 42, 919-924.	0.7	10
990	Use of pulsed electron avalanche knife (PEAK) PlasmaBlade <sup>®</sup> in patients undergoing implantation of subcutaneous implantable cardioverter-defibrillator. <i>IJC Heart and Vasculature</i> , 2019, 24, 100390.	0.6	3
991	Cardiac resynchronization therapy reprogramming to improve electrical synchrony in patients with existing devices. <i>Journal of Electrocardiology</i> , 2019, 56, 94-99.	0.4	13
992	Implantation of left atrial-ventricular epicardial pacemaker system and subcutaneous implantable cardioverter-defibrillator in a single setting: The "extravascular" cardiac resynchronization therapy. <i>HeartRhythm Case Reports</i> , 2019, 5, 354-358.	0.2	2
993	2D/3D Echocardiographic features of patients with reverse remodeling after cardiac resynchronization therapy. <i>Echocardiography</i> , 2019, 36, 1475-1481.	0.3	3
994	Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay Versus Right Bundle Branch Block. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3082-3099.	1.2	21



#	ARTICLE	IF	CITATIONS
995	Sleep-disordered breathing and effectiveness of cardiac resynchronization therapy in heart failure patients: gender differences?. <i>Sleep Medicine</i> , 2019, 64, 106-111.	0.8	3
996	Precision and reproducibility of non-automatic measurement of the QRS complex in potential candidates for cardiac resynchronization therapy. <i>Journal of Electrocardiology</i> , 2019, 57, 90-94.	0.4	2
997	Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1799.	3.8	32
998	Sex differences in cardiometabolic disorders. <i>Nature Medicine</i> , 2019, 25, 1657-1666.	15.2	244
999	Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. <i>Journal of the American Heart Association</i> , 2019, 8, e013539.	1.6	30
1000	The desire for physiological pacing: Are we there yet?. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 3025-3038.	0.8	3
1001	Devices in Heart Failure Patients—Who Benefits From ICD and CRT?. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 111.	1.1	17
1002	Clinical Indications for Therapeutic Cardiac Devices. , 2019, , .		1
1003	Cardiac resynchronization therapy-heart failure (CRT-HF) clinic: A novel model of care. <i>PLoS ONE</i> , 2019, 14, e0222610.	1.1	20
1004	Delivery of cardiac resynchronization therapy via the left inferior phrenic vein: a case report. <i>European Heart Journal - Case Reports</i> , 2019, 3, ytz144.	0.3	2
1005	Clinical Controversies in Device Therapy for Cardiac Arrhythmias. , 2019, , .		0
1006	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2019, 7, 878-887.	1.9	37
1007	Cardiac Resynchronization in Women. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1036-1044.	1.3	12
1008	Why Dyssynchrony Matters in Heart Failure?. <i>Cardiac Electrophysiology Clinics</i> , 2019, 11, 39-47.	0.7	9
1009	Predicting defibrillator benefit in patients with cardiac resynchronization therapy: A competing risk study. <i>Heart Rhythm</i> , 2019, 16, 1057-1064.	0.3	7
1010	Updated Clinical Evidence for Effective Cardiac Resynchronization Therapy in Congestive Heart Failure and Timing of Implant. <i>Cardiac Electrophysiology Clinics</i> , 2019, 11, 55-65.	0.7	1
1011	Gender-Based Differences in Cardiac Resynchronization Therapy Response. <i>Cardiac Electrophysiology Clinics</i> , 2019, 11, 115-122.	0.7	7
1012	Benefits of Multisite/Multipoint Pacing to Improve Cardiac Resynchronization Therapy Response. <i>Cardiac Electrophysiology Clinics</i> , 2019, 11, 99-114.	0.7	7

#	ARTICLE	IF	CITATIONS
1013	Cardiac Implantable Electronic Device Therapy in Heart Failure. <i>Circulation Research</i> , 2019, 124, 1584-1597.	2.0	37
1014	Mortality and Heart Failure After Upgrade to Cardiac Resynchronization Therapy. <i>CJC Open</i> , 2019, 1, 93-99.	0.7	1
1015	Medical Versus Implanted Device Therapy for Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007455.	2.1	0
1016	Long term outcomes in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1979-1983.	0.8	2
1017	Use of Cardiac Resynchronization Therapy Defibrillator in US Hospitals. <i>JAMA Cardiology</i> , 2019, 4, 804.	3.0	6
1018	His-bundle pacing: impact of social media. <i>Europace</i> , 2019, 21, 1445-1450.	0.7	14
1019	Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: a systematic review and meta-analysis of observational studies. <i>Open Heart</i> , 2019, 6, e000937.	0.9	19
1020	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , 2019, 140, e294-e324.	1.6	342
1021	Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e006951.	2.1	13
1022	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2019, 25, 584-619.	0.7	56
1023	Change in indication for cardiac resynchronization therapy?. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, i11-i16.	0.6	8
1024	Dilated cardiomyopathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, 32.	18.1	347
1025	Occurrence, mortality and predictors of complicated cardiac perforation in patients with CRT-D: Based on the National Inpatient Sample registry. <i>International Journal of Cardiology</i> , 2019, 293, 109-114.	0.8	1
1026	The Past, Present and Future of Cardiac Resynchronization Therapy. <i>Korean Circulation Journal</i> , 2019, 49, 384.	0.7	11
1028	Device Therapy in the Heart Failure. <i>Cardiovascular Medicine</i> , 2019, , 129-153.	0.0	1
1029	&lt;p&gt;Modified frailty as a novel factor in predicting the response to cardiac resynchronization in the elderly population&lt;/p&gt;. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 437-443.	1.3	8
1030	Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. <i>Lancet, The</i> , 2019, 393, 1045-1055.	6.3	48
1031	Update on heart failure management and future directions. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 11-43.	0.7	84

#	ARTICLE	IF	CITATIONS
1032	When to choose cardiac resynchronization therapy in chronic heart failure: type and duration of the conduction delay. <i>European Heart Journal Supplements</i> , 2019, 21, B31-B35.	0.0	2
1033	Re-Evaluating the electrovectorcardiographic criteria for left bundle branch block. <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12644.	0.5	7
1034	Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 1020-1030.	0.4	0
1035	Clinical outcomes of cardiac resynchronization therapy with and without a defibrillator in elderly patients with heart failure. <i>Journal of Arrhythmia</i> , 2019, 35, 61-69.	0.5	4
1036	Contemporary practice of CRT implantation in scandinavia compared to Europe. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 9-13.	0.4	1
1037	Predicting response to cardiac resynchronization therapy: Use of strict left bundle branch block criteria. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 431-438.	0.5	10
1038	Cardiac Device Implantation Complications: A Gap in the Quality of Care?. <i>Annals of Internal Medicine</i> , 2019, 171, 368.	2.0	2
1039	Impact of cardiac resynchronisation therapy on burden of hospitalisations and survival: a retrospective observational study in the Northern Region of New Zealand. <i>BMJ Open</i> , 2019, 9, e025634.	0.8	2
1040	Current Pathophysiological and Genetic Aspects of Dilated Cardiomyopathy. , 2019, , .		0
1041	Cardiac Resynchronization Therapy- Single center experience in Nepal. <i>Nepalese Heart Journal</i> , 2019, 16, 5-9.	0.0	0
1042	Cardiac resynchronization in Poland – comparable procedural routines? Insights from CRT Survey II. <i>Postepy W Kardiologii Interwencyjnej</i> , 2019, 15, 477-484.	0.1	0
1043	Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy. <i>Journal of Thoracic Disease</i> , 2019, 11, 5362-5371.	0.6	7
1044	Comparison of Usefulness of Cardiac Resynchronization Therapy in Patients With Type 1 Myotonic Dystrophy With Versus Without Left Bundle Branch Block. <i>American Journal of Cardiology</i> , 2019, 124, 1770-1774.	0.7	11
1045	Vitamin D Deficiency Predicts Poor Clinical Outcomes in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy. <i>Disease Markers</i> , 2019, 2019, 1-7.	0.6	8
1046	8. Grundlagen der Therapie mit einem internen Kardioverter-Defibrillator (ICD), der kardialen Resynchronisationstherapie (CRT) und der kardialen Kontraktilitätsmodulation (CCM). , 2019, , 132-153.		0
1047	MitraClip: How Do We Reconcile the Inconsistent Findings of MITRA-FR and COAPT?. <i>Current Cardiology Reports</i> , 2019, 21, 150.	1.3	8
1048	Secondary mitral regurgitation. <i>Current Opinion in Cardiology</i> , 2019, 34, 185-193.	0.8	0
1049	Meta-Analysis of the Effects of Cardiac Rehabilitation on Exercise Tolerance and Cardiac Function in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	14

#	ARTICLE	IF	CITATIONS
1050	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure – Digest Version. Circulation Journal, 2019, 83, 2084-2184.	0.7	446
1051	The Evolving Role of Electrocardiography in Cardiac Resynchronization Therapy. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 91.	0.4	7
1052	Clinical outcomes and mortality in old and very old patients undergoing cardiac resynchronization therapy. PLoS ONE, 2019, 14, e0225612.	1.1	4
1053	An Update on Pacemakers and Defibrillators. Journal for Nurse Practitioners, 2019, 15, 26-33.e2.	0.4	2
1054	Contemporary Treatment of Heart Failure. Cardiac Electrophysiology Clinics, 2019, 11, 21-37.	0.7	3
1055	Cardiac Resynchronization Therapy in Preserved to Mildly Reduced Systolic Function. Cardiac Electrophysiology Clinics, 2019, 11, 141-146.	0.7	2
1056	Effect of Cardiac Resynchronization Therapy on Left Ventricular Remodeling in Patients With Cardiac Sarcoidosis. American Journal of Cardiology, 2019, 123, 329-333.	0.7	17
1057	Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in Women. Heart Failure Clinics, 2019, 15, 109-125.	1.0	7
1058	Response to cardiac resynchronization therapy in non-ischemic cardiomyopathy is unrelated to medical therapy. Clinical Cardiology, 2019, 42, 143-150.	0.7	2
1059	Multipoint left ventricular pacing improves response to cardiac resynchronization therapy with and without pressure-volume loop optimization: comparison of the long-term efficacy of two different programming strategies. Journal of Interventional Cardiac Electrophysiology, 2019, 54, 141-149.	0.6	6
1060	Left Ventricular Endocardial Pacing/Leadless Pacing. Cardiac Electrophysiology Clinics, 2019, 11, 155-164.	0.7	5
1061	Outcomes of cardiac resynchronization therapy in patients with atrial fibrillation accompanied by slow ventricular response. PLoS ONE, 2019, 14, e0210603.	1.1	6
1062	Left bundle branch block in dilated cardiomyopathy with intermediate left ventricular dysfunction: Clinical phenotyping and outcome correlates. International Journal of Cardiology, 2019, 278, 180-185.	0.8	4
1063	Positive impact of pulmonary vein isolation on biventricular pacing in nonresponders to cardiac resynchronization therapy. Heart Rhythm, 2019, 16, 416-423.	0.3	6
1064	Assessment of mechanical dyssynchrony can improve the prognostic value of guideline-based patient selection for cardiac resynchronization therapy. European Heart Journal Cardiovascular Imaging, 2019, 20, 66-74.	0.5	51
1065	Implantable cardioverter-defibrillator use in elderly patients receiving cardiac resynchronization: A meta-analysis. Hellenic Journal of Cardiology, 2019, 60, 276-281.	0.4	9
1066	A troubled marriage: When electrical and mechanical dyssynchrony don't go along. Journal of Nuclear Cardiology, 2019, 26, 1240-1242.	1.4	10
1067	Impact of Cardiac Resynchronization Therapy on Left Ventricular Unloading in Patients with Implanted Left Ventricular Assist Devices. ASAIO Journal, 2019, 65, 117-122.	0.9	14

#	ARTICLE	IF	CITATIONS
1068	Ventricular synchrony is not significantly determined by absolute myocardial perfusion in patients with chronic heart failure: A $^{13}\text{N}$ -ammonia PET study. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 2234-2242.	1.4	2
1069	Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 115-123.	1.5	4
1070	Prognostic effect and modulation of cardiac sympathetic function in heart failure patients treated with cardiac resynchronization therapy. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 283-290.	1.4	12
1071	Sex Differences in Electrophysiology, Ventricular Tachyarrhythmia, Cardiac Arrest and Sudden Cardiac Death Following Acute Myocardial Infarction. <i>Heart Lung and Circulation</i> , 2020, 29, 1025-1031.	0.2	14
1072	Cardiac Imaging in Heart Failure. , 2020, , 418-448.e5.		0
1073	Management of Arrhythmias and Device Therapy in Heart Failure. , 2020, , 549-567.		0
1074	Nuclear Imaging of the Cardiac Sympathetic Nervous System. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1036-1054.	2.3	40
1075	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	1.0	4,210
1076	Prognostic Usefulness of Systolic Blood Pressure One-Year Following Cardiac Resynchronization Therapy (from MADIT-CRT). <i>American Journal of Cardiology</i> , 2020, 125, 777-782.	0.7	1
1077	Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. <i>Clinical Cardiology</i> , 2020, 43, 187-195.	0.7	10
1078	Coronary venoplasty during cardiac resynchronization therapy device implantations: Acute results and clinical outcomes. <i>Heart Rhythm</i> , 2020, 17, 736-742.	0.3	7
1079	Stretchable Low-impedance Nanocomposite Comprised of Ag-Au Core-Shell Nanowires and Pt Black for Epicardial Recording and Stimulation. <i>Advanced Materials Technologies</i> , 2020, 5, 1900768.	3.0	43
1080	Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II. <i>Clinical Research in Cardiology</i> , 2020, 109, 832-844.	1.5	3
1081	Cardiac resynchronization and implantable defibrillators in adults with congenital heart disease. <i>Heart Failure Reviews</i> , 2020, 25, 657-670.	1.7	1
1082	Therapies for Advanced Heart Failure Patients Ineligible for Heart Transplantation: Beyond Pharmacotherapy. <i>Canadian Journal of Cardiology</i> , 2020, 36, 234-243.	0.8	6
1083	Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. <i>European Heart Journal</i> , 2020, 41, 1976-1986.	1.0	33
1084	Contemporary approach to treating heart failure. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 507-518.	2.3	9
1085	The risk and prevention of sudden death in patients with heart failure with reduced ejection fraction. <i>Current Opinion in Cardiology</i> , 2020, 35, 138-144.	0.8	5

#	ARTICLE	IF	CITATIONS
1086	Snare technique for coronary sinus cannulation in cardiac resynchronization therapy. <i>Indian Pacing and Electrophysiology Journal</i> , 2020, 20, 293-295.	0.3	2
1087	Targeted Left Ventricular Lead Implantation Strategy for Non-Left Bundle Branch Block Patients. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1171-1181.	1.3	29
1088	The effect of revascularization on mortality and risk of ventricular arrhythmia in patients with ischemic cardiomyopathy. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 455.	0.7	2
1089	Utility of 6-Minute Walk Test to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. <i>American Journal of Cardiology</i> , 2020, 132, 79-86.	0.7	1
1090	Cost-effectiveness of cardiac resynchronization therapy. <i>Journal of Medical Economics</i> , 2020, 23, 1375-1378.	1.0	0
1091	Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the ASCD-HeFT. <i>Journal of the American College of Cardiology</i> , 2020, 76, 405-415.	1.2	43
1092	Sex-Specific Outcomes in Cardiovascular Device Evaluations. <i>Journal of Women's Health</i> , 2020, 29, 1246-1255.	1.5	1
1093	Sex-specific arrhythmia risk of post-MI follow-up. , 2020, , 583-593.		0
1094	CRT and sex-specific registries and metaanalyses. , 2020, , 875-884.		0
1095	Clinical experience with the use of CRT in women. , 2020, , 867-874.		0
1096	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, e159-e240.	1.2	364
1097	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2020, 142, e558-e631.	1.6	263
1098	A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life. <i>ESC Heart Failure</i> , 2020, 7, 2922-2932.	1.4	35
1100	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020, 22, 2370-2379.	2.9	14
1101	Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance. <i>ESC Heart Failure</i> , 2020, 7, 3040-3048.	1.4	3
1102	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e000099.	0.9	45
1103	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	2.9	101
1104	An epicardial bioelectronic patch made from soft rubbery materials and capable of spatiotemporal mapping of electrophysiological activity. <i>Nature Electronics</i> , 2020, 3, 775-784.	13.1	126

#	ARTICLE	IF	CITATIONS
1105	Lateral left ventricular lead position is superior to posterior position in long-term outcome of patients who underwent cardiac resynchronization therapy. <i>ESC Heart Failure</i> , 2020, 7, 3374-3382.	1.4	14
1106	Left ventricle and mitral valve reverse remodeling in response to cardiac resynchronization therapy in nonischemic cardiomyopathy. <i>Echocardiography</i> , 2020, 37, 1557-1565.	0.3	1
1107	Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 634-640.	0.6	1
1108	Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e016309.	1.6	23
1109	Efficacy and Safety of Exercise Rehabilitation for Heart Failure Patients With Cardiac Resynchronization Therapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Physiology</i> , 2020, 11, 980.	1.3	9
1110	Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. <i>ESC Heart Failure</i> , 2020, 7, 2972-2982.	1.4	9
1111	Association of ECG characteristics with clinical and echocardiographic outcome to CRT in a non-LBBB patient population. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 62, 9-19.	0.6	2
1112	Effect of closed loop stimulation versus accelerometer on outcomes with cardiac resynchronization therapy: the CLASS trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 61, 479-485.	0.6	2
1113	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2527-2564.	1.2	41
1114	Reappraisal on pharmacological and mechanical treatments of heart failure. <i>Cardiovascular Diabetology</i> , 2020, 19, 55.	2.7	27
1115	Validation of Three European Risk Scores to Predict Long-Term Outcomes for Patients Receiving Cardiac Resynchronization Therapy in an Asian Population. <i>Journal of Cardiovascular Translational Research</i> , 2020, 14, 754-760.	1.1	0
1116	Comparison of left ventricular lead upgrade vs continued medical care among patients eligible for cardiac resynchronization therapy at the time of defibrillator generator replacement: Predictors of left ventricular lead upgrade and associations with long-term outcomes. <i>Heart Rhythm</i> , 2020, 17, 1878-1886.	0.3	3
1117	Novel two-lead cardiac resynchronization therapy system provides equivalent CRT responses with less complications than a conventional three-lead system: Results from the QP ExCELS lead registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1784-1792.	0.8	6
1118	Update of Non-Pharmacological Therapy for Heart Failure. , 2020, , .		0
1119	The management of atrial fibrillation in heart failure: an expert panel consensus. <i>Heart Failure Reviews</i> , 2020, 26, 1345-1358.	1.7	15
1120	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1247-1258.	2.9	29
1121	The ECG Belt for CRT response trial: Design and clinical protocol. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1063-1071.	0.5	7
1122	Machine Learning of 12-Lead QRS Waveforms to Identify Cardiac Resynchronization Therapy Patients With Differential Outcomes. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008210.	2.1	29



#	ARTICLE	IF	CITATIONS
1123	The efficacy of left bundle branch area pacing compared with biventricular pacing in patients with heart failure: A matched case-control study. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2068-2077.	0.8	60
1124	Left Bundle Branch Block. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008239.	2.1	53
1125	The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT Study. <i>ESC Heart Failure</i> , 2020, 7, 1072-1084.	1.4	13
1126	Handling of Ventricular Fibrillation in the Emergency Setting. <i>Frontiers in Pharmacology</i> , 2019, 10, 1640.	1.6	9
1127	Cardiac resynchronization therapy modulates peripheral sympathetic activity. <i>Heart Rhythm</i> , 2020, 17, 1139-1146.	0.3	3
1128	Alternating QRS Complex Morphology in a Man Presenting With Stroke. <i>JAMA Internal Medicine</i> , 2020, 180, 778.	2.6	0
1129	Combination of Left Ventricular End-Diastolic Diameter and QRS Duration Strongly Predicts Good Response to and Prognosis of Cardiac Resynchronization Therapy. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-8.	0.5	3
1130	Predictors of long-term outcomes greater than 10 years after cardiac resynchronization therapy implantation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1182-1186.	0.8	6
1131	Keeping pace with the competition: His bundle versus biventricular pacing in heart failure. <i>Current Opinion in Cardiology</i> , 2020, 35, 295-307.	0.8	4
1132	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 327-337.	1.3	15
1133	Future research prioritization in cardiac resynchronization therapy. <i>American Heart Journal</i> , 2020, 223, 48-58.	1.2	13
1134	Identifying and Addressing Gaps in the Use of Cardiac Resynchronization Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 739-741.	0.7	1
1136	Association between heart failure aetiology and magnitude of echocardiographic remodelling and outcome of cardiac resynchronization therapy. <i>ESC Heart Failure</i> , 2020, 7, 645-653.	1.4	10
1137	The influence of scar on the spatio-temporal relationship between electrical and mechanical activation in heart failure patients. <i>Europace</i> , 2020, 22, 777-786.	0.7	12
1138	Septal contraction predicts acute haemodynamic improvement and paced QRS width reduction in cardiac resynchronization therapy. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 845-852.	0.5	5
1139	Prognostication of Poor Survival After Cardiac Resynchronization Therapy. <i>Medicina (Lithuania)</i> , 2020, 56, 19.	0.8	3
1140	Need for pacing in patients who qualify for an implantable cardioverter-defibrillator: Clinical implications for the subcutaneous ICD. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12744.	0.5	8
1141	A novel risk model for mortality and hospitalization following cardiac resynchronization therapy in patients with non-ischemic cardiomyopathy: the alpha-score. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 205.	0.7	3

#	ARTICLE	IF	CITATIONS
1143	Implantable Cardioverter-Defibrillators in Trials of Drug Therapy for Heart Failure: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e015177.	1.6	9
1144	Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 57-68.	1.0	4
1145	The relation between cardiac <sup>123I</sup> -MIBG scintigraphy and functional response 1 year after CRT implantation. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 49-57.	0.5	9
1146	High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland. <i>Archives of Medical Science</i> , 2021, 17, 675-681.	0.4	3
1147	The rationale for repurposing funny current inhibition for management of ventricular arrhythmia. <i>Heart Rhythm</i> , 2021, 18, 130-137.	0.3	3
1148	Biventricular pacemaker and defibrillator implantation in patients with chronic heart failure in China. <i>ESC Heart Failure</i> , 2021, 8, 546-554.	1.4	7
1149	The evolution of cardiac resynchronization therapy and an introduction to conduction system pacing: a conceptual review. <i>Europace</i> , 2021, 23, 496-510.	0.7	23
1150	Upgrade from implantable cardioverter-defibrillator vs. <i>de novo</i> implantation of cardiac resynchronization therapy: long-term outcomes. <i>Europace</i> , 2021, 23, 113-122.	0.7	5
1151	Fusion pacing in patients with right bundle branch block who undergo cardiac resynchronization therapy. <i>Journal of Electrocardiology</i> , 2021, 64, 66-71.	0.4	6
1152	Comprehensive plasma metabolites profiling reveals phosphatidylcholine species as potential predictors for cardiac resynchronization therapy response. <i>ESC Heart Failure</i> , 2021, 8, 280-290.	1.4	6
1153	Association between CRT(D)/ICD and renal insufficiency: A systematic review and meta-analysis. <i>Seminars in Dialysis</i> , 2021, 34, 17-30.	0.7	8
1154	Cardiac resynchronisation therapy in patients with left bundle branch block with residual conduction. <i>Indian Pacing and Electrophysiology Journal</i> , 2021, 21, 14-17.	0.3	1
1155	Clinical manifestations of device-related infective endocarditis in cardiac resynchronization therapy recipients. <i>Archives of Medical Science</i> , 2021, 17, 638-645.	0.4	2
1156	Cardiac resynchronization therapy in heart failure patients: tough road but clear future. <i>Heart Failure Reviews</i> , 2021, 26, 735-745.	1.7	9
1157	Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy. <i>European Journal of Arrhythmia &amp; Electrophysiology</i> , 2021, 7, 19.	0.2	0
1158	Long-Term Outcomes in Patients With a Left Ejection Fraction $\leq 15\%$ Undergoing Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 36-46.	1.3	7
1159	Mechanical Dyssynchrony with Gated Myocardial Perfusion SPECT: Reproducibility is the Key. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 962-964.	1.4	1
1160	Current Treatment Options in Cardiovascular Medicine Arrhythmia Section From the His Bundle to the Left Bundle: Clinical Applications of Conduction System Pacing. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	1

#	ARTICLE	IF	CITATIONS
1161	Real-world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMART-Registry. ESC Heart Failure, 2021, 8, 1675-1680.	1.4	7
1162	Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2021, 7, 47-49.	1.3	0
1163	Management of Heart Failure Patient with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1131-1139.	2.2	36
1164	Indications for Cardiac Resynchronization Therapy. , 2021, , 287-299.		0
1165	What Are the Expectations for Cardiac Resynchronization Therapy? A Validation of Two Response Definitions. Journal of Clinical Medicine, 2021, 10, 514.	1.0	14
1166	Personalizing heart failure management in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2022, 37, 2055-2062.	0.4	11
1168	Usefulness of Pre-Procedural Imaging of the Coronary Venous System With Coronary Angiography Before Cardiac Resynchronization Therapy. Angiology, 2021, 72, 651-656.	0.8	0
1169	Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. Journal of the American Heart Association, 2021, 10, e018127.	1.6	7
1170	The Benefit of Atrioventricular Junction Ablation for Permanent Atrial Fibrillation and Heart Failure Patients Receiving Cardiac Resynchronization Therapy: An Updated Systematic Review and Meta-analysis. Indian Pacing and Electrophysiology Journal, 2021, 21, 101-111.	0.3	10
1171	Long-term cardiac reverse remodeling after cardiac resynchronization therapy. Journal of Arrhythmia, 2021, 37, 653-659.	0.5	7
1172	Efficacy of Cardiac Resynchronization Therapy in Patients with a Narrow QRS Complex. Journal of Interventional Cardiology, 2021, 2021, 1-7.	0.5	2
1173	Should different ECG QRS duration criteria be used for men and women with heart failure for cardiac resynchronization therapy?. Minerva Cardiology and Angiology, 2021, 69, 64-69.	0.4	1
1174	Cardiac resynchronization therapy with or without defibrillation. Cardiology in Review, 2021, Publish Ahead of Print, .	0.6	0
1175	Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. Canadian Journal of Cardiology, 2021, 37, 560-571.	0.8	40
1176	Bradyarrhythmias and Physiologic Pacing in the ICU. Journal of Intensive Care Medicine, 2021, , 088506662199274.	1.3	3
1178	Cardiac Resynchronization Therapy in Patients with Heart Failure. Heart Failure Clinics, 2021, 17, 289-301.	1.0	3
1179	Permanent His Bundle Pacing in Patients With Congenital Complete Heart Block. JACC: Clinical Electrophysiology, 2021, 7, 522-529.	1.3	14
1180	Cardiac implantable electronic device surgery with interruption of warfarin forgoing post-operative bridging therapy in patients with moderate or high thromboembolic risks. Thrombosis Journal, 2021, 19, 28.	0.9	0

#	ARTICLE	IF	CITATIONS
1181	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. <i>American Heart Journal</i> , 2021, 234, 90-100.	1.2	20
1182	A Novel High-Resolution Surface Electrocardiographic Method to Identify and Characterize Myocardial Scar: A Proof-of-Concept Study. <i>CJC Open</i> , 2021, 3, 1207-1213.	0.7	0
1183	Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008991.	2.1	10
1184	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	0.7	18
1185	Beyond Left Ventricular Ejection Fraction Improvement in the Optimization of Cardiac Resynchronization Therapy. <i>Angiology</i> , 2021, , 000331972110155.	0.8	1
1186	Five-year survival and use of hospital services following ICD and CRT implantation: comparing real-world data with RCTs. <i>ESC Heart Failure</i> , 2021, 8, 2438-2447.	1.4	4
1187	Cardiac resynchronization therapy using a pacemaker or a defibrillator: Patient selection and evidence to support it. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 46-52.	1.6	3
1188	Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 53-60.	1.6	2
1189	Electrical storm: Prognosis and management. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 70-79.	1.6	17
1191	JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. <i>Circulation Journal</i> , 2021, 85, 1104-1244.	0.7	77
1192	Contemporary ICD Use in Patients with Heart Failure. <i>Cardiology and Therapy</i> , 2021, 10, 313-324.	1.1	3
1193	JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. <i>Journal of Arrhythmia</i> , 2021, 37, 709-870.	0.5	91
1194	Bradyarrhythmias in patients with atrial fibrillation and heart failure of reduced ejection fraction: is his bundle pacing superior to biventricular pacing? <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1193-1199.	0.5	13
1195	Impact of Cardiac Resynchronization Therapy on Global and Cardiac Metabolism and Cardiac Mitochondrial Function. <i>Journal of Cardiac Failure</i> , 2021, 27, 706-715.	0.7	1
1196	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, e23-e106.	0.4	33
1197	Redefining the Classifications of Response to Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 871-880.	1.3	33
1199	Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure. <i>World Journal of Cardiology</i> , 2021, 13, 183-203.	0.5	11
1200	Left ventricular lead placement using inner guiding catheter alone in cardiac resynchronization therapy device implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1331-1339.	0.5	2

#	ARTICLE	IF	CITATIONS
1201	Sex differences in CRT device implantation rates, efficacy, and complications following implantation: protocol for a systematic review and meta-analysis of cohort studies. <i>Systematic Reviews</i> , 2021, 10, 210.	2.5	1
1202	The mortality analysis of primary prevention patients receiving a cardiac resynchronization defibrillator (CRT-D) or implantable cardioverter-defibrillator (ICD) according to guideline indications in the improve SCA study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2285-2294.	0.8	1
1203	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2021, 42, 3427-3520.	1.0	899
1204	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the <sc>KaRen</sc> study. <i>ESC Heart Failure</i> , 2021, 8, 4243-4254.	1.4	13
1205	Long-Term Impact of Body Mass Index on Survival of Patients Undergoing Cardiac Resynchronization Therapy: A Multi-Centre Study. <i>American Journal of Cardiology</i> , 2021, 153, 79-85.	0.7	0
1206	Efficacy of His Bundle Pacing on LV Relaxation and Clinical Improvement in HF and LBBB. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 59-69.	1.3	14
1207	Ventricular activation patterns during intrinsic conduction and right ventricular pacing in cardiac resynchronization therapy patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1663-1670.	0.5	1
1208	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>Europace</i> , 2022, 24, 71-164.	0.7	370
1209	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
1210	Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. <i>Russian Journal of Cardiology</i> , 2021, 26, 4600.	0.4	31
1211	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. <i>Europace</i> , 2022, 24, 48-57.	0.7	10
1212	Sex, Race, and Age Differences of Cardiovascular Outcomes in Cardiac Resynchronization Therapy RCTs: A Systematic Review and Meta-analysis. <i>CJC Open</i> , 2021, 3, S192-S201.	0.7	2
1213	Sex, Race, and Age Differences in Cardiovascular Outcomes in Implantable Cardioverter-Defibrillator Randomized Controlled Trials: A Systematic Review and Meta-analysis. <i>CJC Open</i> , 2021, 3, S209-S217.	0.7	2
1214	Cardiac resynchronization therapy for electrical dyssynchrony with a narrow QRS duration and left anterior hemiblock. <i>Heart Rhythm Case Reports</i> , 2021, 7, 829-832.	0.2	3
1215	Cardiac Resynchronization Therapy and Cardiac Contractility Modulation in Patients with Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 599-606.	1.0	5
1216	Simple electrophysiological predictor of QRS change induced by cardiac resynchronization therapy: A novel marker of complete left bundle branch block. <i>Heart Rhythm</i> , 2021, 18, 1717-1723.	0.3	4
1217	His Bundle and Physiologic Pacing for Cardiac Resynchronization Therapy. , 2021, , 323-335.		0
1218	Partial versus complete left bundle branch block, does it impact the outcomes with cardiac resynchronization therapy?. <i>Indian Pacing and Electrophysiology Journal</i> , 2021, 21, 18.	0.3	0

#	ARTICLE	IF	CITATIONS
1219	Comparison of <i>de novo</i> versus upgrade cardiac resynchronisation therapy on clinical effect and long-term outcome. <i>Acta Cardiologica</i> , 2021, 76, 993-1000.	0.3	2
1221	Cardiac Resynchronization Therapy for Heart Failure. , 2020, , 607-612.		1
1222	Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 204-212.	1.9	30
1223	Percutaneous Atriotomy for Left Atrial Coronary Sinus Shunting in Symptomatic Heart Failure. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1236-1247.	1.1	33
1225	Avoiding non-responders to cardiac resynchronization therapy: a practical guide. <i>European Heart Journal</i> , 2017, 38, ehw270.	1.0	190
1226	Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 110-123.	0.8	20
1227	An Open-Access ECG Database for Algorithm Evaluation of QRS Detection and Heart Rate Estimation. <i>Journal of Medical Imaging and Health Informatics</i> , 2019, 9, 1853-1858.	0.2	36
1228	Impact of Etiology on the Outcomes in Heart Failure Patients Treated with Cardiac Resynchronization Therapy: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e94614.	1.1	23
1229	Comparison of Conventional versus Steerable-Catheter Guided Coronary Sinus Lead Positioning in Patients Undergoing Cardiac Resynchronization Device Implantation. <i>PLoS ONE</i> , 2015, 10, e0143292.	1.1	10
1230	Association between Progressive Intraventricular Conduction Disturbance and Cardiovascular Events. <i>PLoS ONE</i> , 2016, 11, e0157412.	1.1	2
1231	Clinical decision tool for CRT-P vs. CRT-D implantation: Findings from PROSE-ICD. <i>PLoS ONE</i> , 2017, 12, e0175205.	1.1	8
1232	The impact of gender difference on clinical and echocardiographic outcomes in patients with heart failure after cardiac resynchronization therapy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0176248.	1.1	23
1233	Indications of Cardiac Resynchronization in Non-Left Bundle Branch Block: Clinical Review of Available Evidence. <i>Cardiology Research</i> , 2020, 11, 1-8.	0.5	5
1234	Developments in Cardiac Resynchronisation Therapy. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 04, 122.	1.3	7
1235	2020 Clinical practice guidelines for Chronic heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 4083.	0.4	229
1236	2020 Clinical practice guidelines for Chronic heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 4083.	0.4	32
1237	Six Sigma DMAIC for Shaking Stagnant Construction Cultures – A Conceptual Perspective. <i>Journal of Civil Engineering and Environmental Sciences</i> , 0, , 013-020.	0.7	1
1238	CARDIAC RESYNCHRONIZATION THERAPY. INDICATIONS AND NOVEL APPROACHES TO THE IMPROVEMENT OF ITS EFFICIENCY. <i>Complex Issues of Cardiovascular Diseases</i> , 2018, 7, 102-116.	0.3	5



#	ARTICLE	IF	CITATIONS
1241	Advances in Cardiac Resynchronization Therapy. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3681-3693.	0.2	4
1242	Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure. Current Pharmaceutical Design, 2014, 21, 1011-1029.	0.9	4
1244	The Treatment of Heart Failure with Reduced Ejection Fraction. Deutsches A&#x0308;rztblatt International, 2020, 117, 376-386.	0.6	37
1245	Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-560.	1.3	58
1246	Focused Update of 2016 Korean Society of Heart Failure Guidelines for the Management of Chronic Heart Failure. International Journal of Heart Failure, 2019, 1, 4.	0.9	45
1247	Electrocardiographic Parameters as Predictors of Response to Cardiac Resynchronization Therapy. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 297-302.	0.1	5
1248	An early proof-of-concept of cardiac resynchronization therapy. World Journal of Cardiology, 2011, 3, 374.	0.5	2
1249	Outcome of patients with cardiac resynchronisation defibrillator therapy and a follow-up of at least five years after implant. Swiss Medical Weekly, 2014, 144, w13938.	0.8	1
1250	The advent of cardiac resynchronization therapy has created a confusing terminology of heart failure. Cardiology Journal, 2012, 19, 11-14.	0.5	1
1251	Long-term outcomes of cardiac resynchronization therapy are worse in patients who require atrioventricular junction ablation for atrial fibrillation than in those with sinus rhythm. Cardiology Journal, 2014, 21, 309-315.	0.5	14
1252	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Acta Cardiologica Sinica, 2019, 35, 244-283.	0.1	50
1253	Critical Questions about PARADIGM-HF and the Future. Acta Cardiologica Sinica, 2016, 32, 387-96.	0.1	17
1254	Application of Cardiac Resynchronization Therapy in Patients with Heart Failure. Advances in Clinical Medicine, 2021, 11, 4554-4559.	0.0	0
1255	Ventricular Arrhythmias in Seniors with Heart Failure: Present Dilemmas and Therapeutic Considerations: A Systematic Review. Current Cardiology Reviews, 2022, 18, .	0.6	2
1256	Implantable Cardiac Devices. , 2010, , 1025-1035.		1
1257	5i1/4Žã¿fã,â...ã«ãšãã,ãfãfã,ã,1æ²»ç™,ã©ç³/4çš¶ã±±æœ. Japanese Journal of Electrocardiology, 2011, 31, 376-386.		0
1258	Clinical Trials of Cardiac Resynchronization Therapy. , 2011, , 279-299.		0
1259	Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology. Materia Socio-medica, 2011, 23, 147.	0.3	0





#	ARTICLE	IF	CITATIONS
1286	Cardiac resynchronization therapy in acute pulmonary edema: A case report. <i>World Journal of Cardiology</i> , 2013, 5, 355.	0.5	0
1287	Heart Failure (or Congestive Heart Failure). , 2013, , 81-92.		0
1288	Algorithm for Treatment of Advanced Heart Failure. , 2013, , 9-34.		0
1290	Acute effects of cardiac resynchronization therapy on arterial distensibility and serum norepinephrine levels in advanced heart failure. <i>Cardiology Journal</i> , 2013, 20, 304-309.	0.5	1
1291	Implantable Cardioverter and Defibrillator Therapy. , 2014, , 239-251.		0
1293	Changes in renal function over time in patients with cardiac resynchronisation therapy. <i>Swiss Medical Weekly</i> , 2013, 143, w13863.	0.8	1
1294	Cardiac Resynchronization Therapy: Do Benefits Justify the Costs and Are They Sustained Over the Long Term?. , 2014, , 629-638.		0
1295	Coronary revascularization and cardiac resynchronization therapy in ischemic cardiomyopathy patients. <i>Journal of the Japanese Coronary Association</i> , 2014, 20, 57-61.	0.0	0
1296	Almanac 2013: Heart failure the national society journals present selected research that has driven recent advances in clinical cardiology. <i>Srce I Krvni Sudovi</i> , 2014, 33, 273-278.	0.1	0
1297	Device Therapy for Ventricular Arrhythmias in Patients with Ischemic Heart Disease. <i>Japanese Journal of Electrocardiology</i> , 2014, 34, 137-143.	0.0	0
1298	Aging and Optimal Therapy of Systolic Heart Failure in the Elderly. , 2014, , 47-63.		0
1301	Use of Cardiac Resynchronisation Therapy â€œ Change of Clinical Settings. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 20-24.	1.3	1
1302	Current Evidence and Recommendations for Cardiac Resynchronisation Therapy. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 9-14.	1.3	2
1303	Usefulness of a novel active fixation left ventricle lead in cardiac resynchronization therapy. <i>Case Reports in Internal Medicine</i> , 2014, 1, .	0.0	0
1304	Markers of Cardiac Resynchronization Therapy. , 2015, , 1-30.		0
1305	Device Therapy in Heart Failure. , 2015, , 167-177.		0
1306	Cardiac Resynchronization Therapy and Possible Dysfunctions. , 2015, , 109-116.		0
1307	Implanteerbare devices bij hartfalen. , 2015, , 85-98.		0

#	ARTICLE	IF	CITATIONS
1308	Six Sigma DMAIC for Shaking Stagnant Construction Cultures – A Conceptual Perspective. Journal of Civil Engineering and Environmental Sciences, 2015, 1, 013-020.	0.7	0
1309	Current Technology to Maximize Cardiac Resynchronization Therapy Benefit for Patients With Symptomatic Heart Failure. AACN Advanced Critical Care, 2015, 26, 329-340.	0.6	1
1311	Schrittmacher und Defibrillatoren. , 2016, , 79-88.		0
1312	Markers of Cardiac Resynchronization Therapy. , 2016, , 955-984.		0
1313	Cardiac Resynchronization Therapy. , 2016, , 293-310.		1
1314	Positive Response to Cardiac Resynchronization Therapy - The Role of NT-proBNP. International Journal of Cardiovascular Research, 2016, 05, .	0.1	1
1315	Cardiac Resynchronization Therapy in Graft Failure. , 2016, , 623-635.		0
1317	Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy. Korean Journal of Medicine, 2016, 90, 210-216.	0.1	1
1319	Terapia de resincronizaci3n card3aca con o sin cardiodesfibrilador versus terapia con desfibrilador autom3tico, Pereira (Colombia): un estudio de cohorte. Iatreia, 2016, 29, .	0.1	2
1320	Biventricular Pacing in Women for Heart Failure. , 2017, , 189-201.		0
1321	An electromechanical hug for the failing heart. Annals of Translational Medicine, 2016, 4, 412-412.	0.7	0
1322	A Primer on Cardiac Devices: Psychological and Pharmacological Considerations. Psychiatric Annals, 2016, 46, 683-690.	0.1	0
1323	Usefulness of Intracardiac Local Ventricular Electrogram to Predict Responders in Patients Undergoing Cardiac Resynchronization Therapy. The Showa University Journal of Medical Sciences, 2017, 29, 131-139.	0.1	0
1324	An3sthesie bei Patienten mit Shuntvitien. , 2017, , 1-8.		0
1325	Cardiac Resynchronization Therapy in Heart Failure. , 2017, , 385-402.		0
1326	Acute Decompensated Heart Failure: Treatment with Guideline Directed Medical Therapy and Discharge Planning. , 2017, , 285-308.		0
1327	An3sthesie bei Patienten mit Herzinsuffizienz. , 2017, , 1-14.		0
1328	Advanced Therapies: Cardiac Resynchronization Therapy for Heart Failure. , 2017, , 341-359.		0

#	ARTICLE	IF	CITATIONS
1329	The Impact of Cardiac Resynchronization Therapy in the Treatment of Heart Failure. , 0, , .		0
1330	AnÄsthesie bei Patienten mit Herzschrittmachern und implantierbaren Kardioverter-Defibrillatoren (ICD). , 2018, , 1-13.		0
1331	Chronic Chagas Cardiomyopathy Patients and Resynchronization Therapy: a Survival Analysis. Brazilian Journal of Cardiovascular Surgery, 2018, 33, 82-88.	0.2	7
1332	OBSOLETE: Lead-Related Complications. , 2018, , .		0
1333	Acute and Chronic Heart Failure. , 2018, , 237-252.		0
1334	Optimal Strategies for Mitigating Sudden Cardiac Death Risk in At-risk Patients with Structural Heart Disease. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3025-3032.	0.2	0
1335	Chronische Herzinsuffizienz. , 2018, , 80-93.		0
1336	Relationship of Electromechanical Dyssynchrony in Patients Submitted to CRT With LV Lead Implantation Guided by Gated Myocardial Perfusion Spect. Arquivos Brasileiros De Cardiologia, 2018, 111, 607-615.	0.3	2
1337	Do We Need an Implantable Cardioverter-defibrillator for Primary Prevention in Cardiac Resynchronisation Therapy Patients?. Arrhythmia and Electrophysiology Review, 2018, 7, 157.	1.3	2
1338	OBSOLETE: Cardiac Resynchronization Therapy. , 2018, , .		0
1339	OBSOLETE: Cardiac Arrhythmias in Heart Failure. , 2018, , .		0
1340	Cardiac Disease in Older Adults. , 2018, , 1-21.		0
1341	Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy. The Cochrane Library, 2018, 2018, CD012738.	1.5	12
1342	Cardiac Resynchronization Therapy for Heart Failure in Patients Without LeftÂBundle Branch Block. , 2019, , 39-55.		0
1343	Current Management and Treatment. , 2019, , 199-215.		1
1344	AnÄsthesie bei Patienten mit Herzschrittmachern und implantierbaren Kardioverter-Defibrillatoren (ICD). Springer Reference Medizin, 2019, , 1633-1645.	0.0	0
1345	Biventricular Pacing for Patients with Complete Heart Block. , 2019, , 57-76.		0
1346	Cardiac resynchronization therapy: a comprehensive review. Minerva Medica, 2019, 110, 121-138.	0.3	4

#	ARTICLE	IF	CITATIONS
1347	CAPABILITIES OF <sup>123</sup> I-MIBG SCINTIGRAPHY AND GATED BLOOD-POOL SPECT IN PREDICTING THE RESULTS OF CARDIAC RESYNCHRONIZATION THERAPY. Siberian Medical Journal, 2019, 34, 63-70.	0.3	0
1348	Cardiac Resynchronization Therapy <sup>1/4</sup> CRT <sup>1/4</sup> for Chronic Heart Failure. The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders, 2019, 39, 33-38.	0.1	0
1351	Can a New Algorithm of Cardiac Resynchronization Therapy (Adaptive CRT) Expand Its Utility?. Circulation Journal, 2019, 84, 11-12.	0.7	0
1352	The Evolution of Resynchronization Therapy. , 2020, , 461-469.		0
1353	Representative Databases for Feature Engineering and Computational Intelligence in ECG Processing. , 2020, , 13-29.		3
1357	Anticoagulant therapy in elderly patients and cardiac implantable electronic devices. In A Good Rythm, 2020, 2, 29-34.	0.0	0
1358	Evaluation of an Integrated Device Diagnostics Algorithm to Risk Stratify Heart Failure Patientsâ€• Results From the SCAN-HF Study â€•. Circulation Journal, 2020, 84, 1118-1123.	0.7	1
1359	The Care of Patients With Atrial Fibrillation and Heart Failure. Critical Pathways in Cardiology, 2021, 20, 93-99.	0.2	1
1360	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
1361	Better CRT Response in Patients Who Underwent Atrioventricular Node Ablation or Upgrade From Pacemaker: A Nomogram to Predict CRT Response. Frontiers in Cardiovascular Medicine, 2021, 8, 760195.	1.1	0
1362	The past, present, and future of implantable cardioverter-defibrillators. , 2020, , 669-681.		0
1363	Predictors of response to cardiac resynchronization therapy in patients with chronic right ventricular pacing. Clinical Research in Cardiology, 2021, 110, 877-883.	1.5	3
1364	Cardiac resynchronisation therapy for reversal of new-onset left bundle branch block and heart failure after surgical aortic valve replacement. BMJ Case Reports, 2020, 13, e238130.	0.2	0
1365	Cardiac Disease in Older Adults. , 2020, , 229-249.		0
1366	Cardiac resynchronization therapy and device-based cardiac contractility modulation. , 2020, , 55-84.		0
1367	Explaining Sex Differences in Cardiac Resynchronisation Therapy Outcome. European Journal of Arrhythmia & Electrophysiology, 2020, 6, 17.	0.2	1
1368	Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study. Cardiology Journal, 2020, 26, 711-716.	0.5	1
1369	Prolonged QRS independently predicts long-term all-cause mortality in patients with narrow QRS complex undergoing coronary artery bypass grafting surgery (9-year follow-up results). Kardiochirurgia I Torakochirurgia Polska, 2020, 17, 117-122.	0.1	1

#	ARTICLE	IF	CITATIONS
1370	Cardiac Resynchronization Therapy. Contemporary Cardiology, 2020, , 569-595.	0.0	0
1371	CRT/ICD. , 2020, , 17-24.		0
1372	ERKRANKUNGEN DES HERZENS UND DES KREISLAUFS. , 2020, , D-1-D17-4.		0
1374	Nonpharmacological Treatment of Atrial Fibrillation: What Is the Role of Device Therapy?. International Journal of Angiology, 2020, 29, 113-122.	0.2	0
1375	Coronary Sinus Phlebography in Cardiac Resynchronization Therapy Patients: Identifying and Solving Demanding Cases. Journal of Innovations in Cardiac Rhythm Management, 2020, 11, 4161-4170.	0.2	0
1376	Advanced Heart Failure Management and Selection for Advanced Therapies. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 216-235.	0.3	0
1377	The Usefulness and Limitations of Impedance Cardiography for Cardiac Resynchronization Therapy Device Optimization. International Heart Journal, 2020, 61, 896-904.	0.5	2
1378	Bradycardia and Pacemakers/CRT. , 2021, , 323-338.		0
1379	Cardiac resynchronization therapy: a decade of experience and the dilemma of nonresponders. Texas Heart Institute Journal, 2011, 38, 358-60.	0.1	0
1380	Cardiac implantable electrical devices: bioethics and management issues near the end of life. Ochsner Journal, 2011, 11, 342-7.	0.5	4
1381	Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011. Open Medicine, 2012, 6, e17-23.	1.5	0
1382	Intermediate-term mortality and incidence of ICD therapy in octogenarians after cardiac resynchronization therapy. Journal of Geriatric Cardiology, 2014, 11, 180-4.	0.2	8
1383	Cardiac resynchronization therapy: history, present status, and future directions. Ochsner Journal, 2014, 14, 596-607.	0.5	26
1384	An Overview of Current Cardiac Resynchronization Therapy. Acta Cardiologica Sinica, 2013, 29, 496-504.	0.1	1
1385	The role of electrocardiography in the elaboration of a new paradigm in cardiac resynchronization therapy for patients with nonspecific intraventricular conduction disturbance. Journal of Geriatric Cardiology, 2016, 13, 118-25.	0.2	3
1386	Heart Failure With Reduced Ejection Fraction And A Narrow QRS Complex: Combination Of A Subcutaneous Defibrillator With Cardiac Contractility Modulation. Journal of Atrial Fibrillation, 2015, 8, 1081.	0.5	2
1387	Optimizing CRT - Do We Need More Leads and Delivery Methods. Journal of Atrial Fibrillation, 2015, 7, 1202.	0.5	0
1388	ECG Patterns In Cardiac Resynchronization Therapy. Journal of Atrial Fibrillation, 2015, 7, 1214.	0.5	4

#	ARTICLE	IF	CITATIONS
1389	Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?. Journal of Atrial Fibrillation, 2015, 8, 1238.	0.5	3
1390	Pre-Implant Assessment For Optimal LV Lead Placement In CRT: ECG, ECHO, or MRI?. Journal of Atrial Fibrillation, 2015, 8, 1280.	0.5	1
1391	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Clinical Management and Outcome. Journal of Atrial Fibrillation, 2013, 5, 748.	0.5	0
1392	Role of Atrio-Ventricular Junction Ablation in Symptomatic Atrial Fibrillation for Optimization of Cardiac Resynchronization Therapy. Journal of Atrial Fibrillation, 2013, 5, 787.	0.5	0
1393	Usefulness of Multisite Ventricular Pacing in Nonresponders to Cardiac Resynchronization Therapy. American Journal of Cardiology, 2022, 164, 86-92.	0.7	6
1394	Left bundle branch pacing in heart failure patients with left bundle branch block: A systematic review and meta-analysis. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 212-218.	0.5	6
1395	Cardiac resynchronization therapy: Current status and near-future prospects. Journal of Cardiology, 2022, 79, 352-357.	0.8	8
1396	Evaluation of electrocardiogram and echocardiographic characteristics of pre-and post-operation of His bundle pacing: A comprehensive review and meta-analysis. , 2021, 25, 845-857.		0
1397	Septal Flash as a Predictor of Cardiac Resynchronization Therapy Response: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Echography, 2021, 31, 198.	0.1	1
1398	Clinical and demographic characteristics of patients with congestive heart failure and implanted devices for cardiac resynchronization therapy. The Siberian Scientific Medical Journal, 2021, 41, 100-108.	0.1	0
1401	Hetero-integration of Silicon Nanomembranes with 2D Materials for Bioresorbable, Wireless Neurochemical System. Advanced Materials, 2022, 34, e2108203.	11.1	28
1402	Economic Issues in Heart Failure in the United States. Journal of Cardiac Failure, 2022, 28, 453-466.	0.7	40
1403	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
1404	Impact of adaptive cardiac resynchronization therapy in patients with systolic heart failure: Beyond QRS duration and morphology. Journal of Cardiology, 2022, 79, 365-370.	0.8	0
1405	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. Heart Failure Reviews, 2022, 27, 1761-1777.	1.7	3
1407	Amuletâ„¢ Shines and Protects; Pacing Battle Intensifies with â€œMore Leads or No Leadsâ€?. Journal of Innovations in Cardiac Rhythm Management, 2022, 13, 4833-4839.	0.2	1
1409	CRT Past, Present, and Future Directions: Toward Intelligent Responders Selection and Optimizing Pacing Modalities. , 0, , .		0
1410	Arrhythmias in Female Patients: Incidence, Presentation and Management. Circulation Research, 2022, 130, 474-495.	2.0	17



#	ARTICLE	IF	CITATIONS
1411	QRS Narrowing Following CRT Implantation: Predictors, Dynamics, and Association with Improved Long-Term Outcome. <i>Journal of Clinical Medicine</i> , 2022, 11, 1279.	1.0	6
1412	Optimal effectiveness of heart failure management – an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure. <i>Heart Failure Reviews</i> , 2022, 27, 1683-1748.	1.7	8
1413	The response to cardiac resynchronization therapy in <sc>LMNA</sc> cardiomyopathy. <i>European Journal of Heart Failure</i> , 2022, 24, 685-693.	2.9	7
1414	Association between biventricular pacing and incidence of ventricular arrhythmias in the early postoperative period after left ventricular assist device implantation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1024-1031.	0.8	3
1415	Sex-related differences in the prognosis of patients with cardiac sarcoidosis treated with cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2022, 19, 1133-1140.	0.3	5
1416	Temporal trends and long-term outcomes among recipients of cardiac resynchronization therapy with defibrillator in the United States, 2011–2015: Insights from the National Cardiovascular Data Registry. <i>Heart Rhythm O2</i> , 2022, 3, 405-414.	0.6	1
1417	Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest. <i>Scientific Reports</i> , 2022, 12, 5685.	1.6	3
1418	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001063.	1.6	756
1419	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, e263-e421.	1.2	774
1420	Prognostic implications of staging cardiac remodeling in patients undergoing cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2022, 355, 65-71.	0.8	6
1421	Strategy for Failed Transvenous Left-Ventricular Lead Placement in Cardiac Resynchronization Therapy: Surrender or Struggle?. <i>Cardiology</i> , 2022, 147, 47-56.	0.6	0
1422	Interventional heart failure therapy: A new concept fighting against heart failure. <i>Journal of Cardiology</i> , 2022, 80, 101-109.	0.8	18
1423	Anodal Capture for Multisite Pacing with a Quadripolar Left Ventricular Lead: A Feasibility Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5886.	1.0	1
1424	Perioperative Sensor and Algorithm Programming in Patients with Implanted ICDs and Pacemakers for Cardiac Resynchronization Therapy. <i>Sensors</i> , 2021, 21, 8346.	2.1	3
1425	Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement. <i>Heart Rhythm O2</i> , 2021, 2, 698-709.	0.6	4
1426	The efficacy and safety outcomes of cardiac resynchronization therapy in patients with heart failure in Thailand: Phramongkutklao experience. <i>Journal of Arrhythmia</i> , 2022, 38, 126-136.	0.5	0
1427	Recent Advances in 1D Nanomaterial-Based Bioelectronics for Healthcare Applications. <i>Advanced NanoBiomed Research</i> , 2022, 2, .	1.7	8
1428	Assessment of left ventricular function with gated myocardial perfusion SPECT and gated myocardial FDG PET in patients with left ventricular mechanical dyssynchrony. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1429	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Española De Cardiología, 2022, 75, 523.e1-523.e114.	0.6	40
1438	A different cardiac resynchronization therapy technique might be needed in some patients with nonspecific intraventricular conduction disturbance pattern.. Journal of Geriatric Cardiology, 2021, 18, 975-985.	0.2	0
1439	Vectorcardiographic QRS area as a predictor of response to cardiac resynchronization therapy.. Journal of Geriatric Cardiology, 2022, 19, 9-20.	0.2	3
1440	Novel electrocardiographic dyssynchrony criteria that may improve patient selection for cardiac resynchronization therapy.. Journal of Geriatric Cardiology, 2022, 19, 31-43.	0.2	1
1441	Electrocardiographic markers of cardiac resynchronization therapy response: delayed time to intrinsicoid deflection onset in lateral leads.. Journal of Geriatric Cardiology, 2022, 19, 21-30.	0.2	1
1442	Evolving concept of dyssynchrony and its utility.. Journal of Geriatric Cardiology, 2022, 19, 44-51.	0.2	1
1449	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Translation of the document prepared by the Czech Society of Cardiology. Cor Et Vasa, 2022, 64, 7-86.	0.1	1
1450	Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial. JACC: Clinical Electrophysiology, 2022, , .	1.3	0
1451	Clinical outcomes of conduction system pacing compared to biventricular pacing in patients requiring cardiac resynchronization therapy. Heart Rhythm, 2022, 19, 1263-1271.	0.3	78
1452	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. European Journal of Heart Failure, 2022, 24, 1080-1090.	2.9	11
1453	Thoracoscopic Implantation of Epicardial Left Ventricular Lead for Cardiac Resynchronization Therapy. Journal of Cardiovascular Development and Disease, 2022, 9, 160.	0.8	4
1454	Status and Update on Cardiac Resynchronization Therapy Trials. Cardiac Electrophysiology Clinics, 2022, 14, 323-343.	0.7	2
1455	Better outcome at lower costs after implementing a CRT-care pathway: comprehensive evaluation of real-world data. ESC Heart Failure, 0, , .	1.4	1
1456	Conduction System Pacing for Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2022, 14, 297-310.	0.7	5
1457	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690.	4.3	109
1458	The Gallantâ€¢ system heart rhythm management device: making a connection. Future Cardiology, 0, , .	0.5	0
1459	What Have We Learned in the Last 20 Years About CRT Non-Responders?. Cardiac Electrophysiology Clinics, 2022, 14, 283-296.	0.7	3
1460	Case Studies of Cardiac Resynchronization Therapy â€¢Nonrespondersâ€¢. Cardiac Electrophysiology Clinics, 2022, 14, 273-282.	0.7	0

#	ARTICLE	IF	CITATIONS
1461	Impact of ventricular arrhythmia management on suboptimal biventricular pacing in cardiac resynchronization therapy. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2023, 66, 353-361.	0.6	1
1462	Fifteen-Year Differences in Indications for Cardiac Resynchronization Therapy in International Guidelines—Insights from the Heart Failure Registries of the European Society of Cardiology. <i>Journal of Clinical Medicine</i> , 2022, 11, 3236.	1.0	2
1463	Profile of nonischemic dilated cardiomyopathy patients with long-term survival ≥10 years on medical therapy alone. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 2389.	0.3	0
1464	Determinants of Response to Cardiac Resynchronization Therapy. , 2022, 13, 4994-5003.		2
1465	Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST CRT Upgrade trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1652-1661.	2.9	9
1466	The value of cardiac sympathetic activity and mechanical dyssynchrony as cardiac resynchronization therapy response predictors: comparison between patients with ischemic and non-ischemic heart failure. <i>Journal of Nuclear Cardiology</i> , 2023, 30, 371-382.	1.4	4
1467	Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1468	Management of Heart Failure in Patients with Chronic Kidney Disease. <i>European Cardiology Review</i> , 0, 17, .	0.7	5
1469	Electrical Dyssynchrony in Cardiac Amyloidosis: Prevalence, Predictors, Clinical Correlates, and Outcomes. <i>Journal of Cardiac Failure</i> , 2022, 28, 1664-1672.	0.7	3
1470	Is Narrowest QRS the Best? A Case of Cardiac Resynchronization Therapy in a Patient with Left Anterior Fascicular Block. <i>PACE - Pacing and Clinical Electrophysiology</i> , 0, , .	0.5	0
1471	Cardiac resynchronization therapy response in cardiac sarcoidosis. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 2072-2080.	0.8	7
1472	Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1711-1722.	1.1	17
1473	Efficacy of the antibacterial envelope to prevent cardiac implantable electronic device infection in a high-risk population. <i>Europace</i> , 2022, 24, 1973-1980.	0.7	9
1474	Death without Previous Hospital Readmission in Patients with Heart Failure with Reduced Ejection Fraction—A New Endpoint from Old Clinical Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 5518.	1.0	0
1475	Assessment of electrical dyssynchrony in cardiac resynchronization therapy: 12-lead electrocardiogram vs. 96-lead body surface map. <i>Europace</i> , 0, , .	0.7	1
1476	Differences in the prognostic value of the electrocardiographic pattern after cardiac resynchronization therapy according to age. <i>Archives of Gerontology and Geriatrics</i> , 2022, , 104826.	1.4	0
1477	Effectiveness and Safety Profile of Remote Pulmonary Artery Hemodynamic Monitoring in a Real-World Veterans Affairs Healthcare System. <i>American Journal of Cardiology</i> , 2022, 184, 56-62.	0.7	2
1478	Cardiac resynchronization considerations in left bundle branch block. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	3

#	ARTICLE	IF	CITATIONS
1479	Three-dimensional electroanatomical mapping guidelines for the selection of pacing site to achieve cardiac resynchronization therapy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1480	Inadvertent QRS prolongation by an optimization device-based algorithm in patients with cardiac resynchronization therapy. <i>PLoS ONE</i> , 2022, 17, e0275276.	1.1	0
1481	Electrocardiographic predictors of echocardiographic response in cardiac resynchronization therapy: Update of an old story. <i>Journal of Electrocardiology</i> , 2022, , .	0.4	0
1482	Ventricular arrhythmia events in heart failure patients with cardiac resynchronization therapy with or without a defibrillator for primary prevention. <i>Journal of Arrhythmia</i> , 0, , .	0.5	1
1483	Clinical versus Echocardiographic Parameters in Assessing Cardiac Resynchronisation Therapy Response in a Multiethnic Asian Population. <i>Annals of the Academy of Medicine, Singapore</i> , 2018, 47, 127-130.	0.2	0
1484	Long Term Outcomes Amongst Non-Progressors to Cardiac Resynchronization Therapy. <i>Heart Rhythm</i> , 2022, , .	0.3	1
1485	Conduction System Disorders Associated With Valvular Heart Disease and Interventions. , 0, , .		0
1486	Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1857-1868.	1.2	10
1487	The Evolving Role of the Cardiac Conduction System in Cardiac Resynchronisation Therapy and Cardiac Pacing. <i>Lecture Notes in Bioengineering</i> , 2022, , 61-80.	0.3	0
1488	Electrocardiogram Belt guidance for left ventricular lead placement and biventricular pacing optimization. <i>Heart Rhythm</i> , 2023, 20, 537-544.	0.3	10
1489	Dyssynchronous Heart Failure: A Clinical Review. <i>Current Cardiology Reports</i> , 2022, 24, 1957-1972.	1.3	2
1490	Association of left ventricular remodeling with cardiac resynchronization therapy outcomes. <i>Heart Rhythm</i> , 2023, 20, 173-180.	0.3	4
1491	Acute echocardiographic and electrocardiographic effects of triggered left ventricular pacing. <i>PLoS ONE</i> , 2022, 17, e0278531.	1.1	0
1492	Success rates, challenges and troubleshooting of left bundle branch area pacing as a cardiac resynchronization therapy for treating patients with heart failure. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1493	Maximizing QRS duration reduction in contemporary cardiac resynchronization therapy is feasible and shorter QRS duration is associated with better clinical outcome. <i>Journal of Interventional Cardiac Electrophysiology</i> , 0, , .	0.6	0
1494	Diretriz Brasileira de Dispositivos Cardíacos Eletrônicos Implantáveis “ 2023. <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.3	1
1495	Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. <i>Circulation</i> , 2023, 147, 812-823.	1.6	7
1496	Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing. <i>Europace</i> , 2023, 25, 1087-1099.	0.7	0

#	ARTICLE	IF	CITATIONS
1497	Cardiac Resynchronization Therapy and Hypertrophic Cardiomyopathy: A Comprehensive Review. <i>Biomedicines</i> , 2023, 11, 350.	1.4	1
1498	Chronic Kidney Disease as a Comorbidity in Heart Failure. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2988.	1.8	9
1499	Sodium perturbs mitochondrial respiration and induces dysfunctional Tregs. <i>Cell Metabolism</i> , 2023, 35, 299-315.e8.	7.2	15
1500	Long-term outcome of cardiac resynchronization therapy patients in the elderly. <i>GeroScience</i> , 2023, 45, 2289-2301.	2.1	1
1501	Outcomes of conduction system pacing for cardiac resynchronization therapy in patients with heart failure: A multicenter experience. <i>Heart Rhythm</i> , 2023, 20, 863-871.	0.3	13
1502	The Value of Left Ventricular Mechanical Dyssynchrony and Scar Burden in the Combined Assessment of Factors Associated with Cardiac Resynchronization Therapy Response in Patients with CRT-D. <i>Journal of Clinical Medicine</i> , 2023, 12, 2120.	1.0	0
1503	Comparison of the relation of the ESC 2021 and ESC 2013 definitions of left bundle branch block with clinical and echocardiographic outcome in cardiac resynchronization therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2023, 34, 1006-1014.	0.8	5
1504	The usefulness of QRS Index for prediction of echocardiographic response in cardiac resynchronization therapy: a multicenter study. <i>Minerva Cardiology and Angiology</i> , 0, , .	0.4	0
1505	Variation in hospital use of cardiac resynchronization therapy-defibrillator among eligible patients and association with clinical outcomes. <i>Heart Rhythm</i> , 2023, 20, 1000-1008.	0.3	2
1506	Power supplies for cardiovascular implantable electronic devices. <i>EcoMat</i> , 2023, 5, .	6.8	9
1507	Predictive value of global longitudinal strain by left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2023, 10, 1937-1947.	1.4	2
1508	A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 33-47.	2.2	0
1509	Comparison of methods for delivering cardiac resynchronization therapy: electrical treatment targets and mechanisms of action. <i>Expert Review of Medical Devices</i> , 2023, 20, 337-348.	1.4	2
1510	Computational Biomechanics of Ventricular Dyssynchrony and Resynchronization Therapy. <i>Cardiac and Vascular Biology</i> , 2023, , 299-336.	0.2	0
1511	Patient-Centered Clinical Trial Design for Heart Failure Devices via Bayesian Decision Analysis. <i>Patient</i> , 2023, 16, 359-369.	1.1	0
1512	Paradigm Shifts in Cardiac Pacing: Where Have We Been and What Lies Ahead?. <i>Journal of Clinical Medicine</i> , 2023, 12, 2938.	1.0	0
1513	The Present Clinical Treatment and Future Emerging Interdisciplinary for Heart Failure: Where we are and What we can do. <i>Intensive Care Research</i> , 2023, 3, 3-11.	0.2	3
1537	Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines. <i>Cardiology and Therapy</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
1541	Recent successes in heart failure treatment. Nature Medicine, 2023, 29, 2424-2437.	15.2	4
1563	Vectorcardiogram Planarity Index Predicts Response to Cardiac Resynchronisation Therapy. , 2023, , .		0